[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 180
1. Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, Hupperets P, Barzan L, de Raucourt D, Chevalier D, Licitra L, Lunghi F, Stupp R, Lacombe D, Bogaerts J, Horiot JC, Bernier J, Vermorken JB, EORTC Head and Neck Cancer Cooperative Group, EORTC Radiation Oncology Group: Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst; 2009 Feb 04;101(3):142-52
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.
  • BACKGROUND: Both induction chemotherapy followed by irradiation and concurrent chemotherapy and radiotherapy have been reported as valuable alternatives to total laryngectomy in patients with advanced larynx or hypopharynx cancer.
  • We report results of the randomized phase 3 trial 24954 from the European Organization for Research and Treatment of Cancer.
  • METHODS: Patients with resectable advanced squamous cell carcinoma of the larynx (tumor stage T3-T4) or hypopharynx (T2-T4), with regional lymph nodes in the neck staged as N0-N2 and with no metastasis, were randomly assigned to treatment in the sequential (or control) or the alternating (or experimental) arm.
  • In the sequential arm, patients with a 50% or more reduction in primary tumor size after two cycles of cisplatin and 5-fluorouracil received another two cycles, followed by radiotherapy (70 Gy total).
  • In the alternating arm, a total of four cycles of cisplatin and 5-fluorouracil (in weeks 1, 4, 7, and 10) were alternated with radiotherapy with 20 Gy during the three 2-week intervals between chemotherapy cycles (60 Gy total).
  • The Kaplan-Meier method was used to obtain time-to-event data.
  • RESULTS: The 450 patients were randomly assigned to treatment (224 to the sequential arm and 226 to the alternating arm).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Chemotherapy, Adjuvant / methods. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Laryngectomy. Radiotherapy, Adjuvant / methods
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Disease-Free Survival. Europe. Female. Fibrosis / etiology. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Laryngeal Edema / etiology. Male. Middle Aged. Mucositis / etiology. Neoplasm Staging. Patient Selection. Radiotherapy Dosage. Recovery of Function. Remission Induction. Research Design. Salvage Therapy / methods. Treatment Failure. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Biometrics. 1975 Mar;31(1):103-15 [1100130.001]
  • [Cites] Biometrics. 1979 Sep;35(3):549-56 [497341.001]
  • [Cites] Cancer. 1983 Apr 15;51(8):1353-5 [6681726.001]
  • [Cites] Cancer. 1984 Sep 1;54(5):811-4 [6204738.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] N Engl J Med. 1992 Oct 15;327(16):1115-21 [1302472.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):265-72 [8158680.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Oral Oncol. 1998 May;34(3):224-8 [9692058.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Oncologist. 2006 Feb;11(2):146-51 [16476835.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1695-704 [17960012.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [CommentIn] J Natl Cancer Inst. 2009 Feb 4;101(3):129-31 [19176460.001]
  • (PMID = 19176454.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00002839
  • [Grant] United States / NCI NIH HHS / CA / 2U10 CA11488-25; United States / NCI NIH HHS / CA / 5U10 CA11488-37
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2724854
  • [Investigator] de Montreuil B; Bensadoun RJ; Buter J; Coche-Dequeant B; Degardin M; Dehesdin D; Duvillard C; Kutem A; Langendiijk JA; Rame JP; Truc G; van den Weynaert D
  •  go-up   go-down


2. Wang HM, Liao CT, Chang TC, Chen JS, Liaw CC, Chen IH, Tsang NM: Biweekly paclitaxel, cisplatin, tegafur, and leucovorin as neoadjuvant chemotherapy for unresectable squamous cell carcinoma of the head and neck. Cancer; 2004 Oct 15;101(8):1818-23
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biweekly paclitaxel, cisplatin, tegafur, and leucovorin as neoadjuvant chemotherapy for unresectable squamous cell carcinoma of the head and neck.
  • BACKGROUND: The goal of the current study was to evaluate the efficacy and toxicity of paclitaxel, cisplatin (P), tegafur (T), and leucovorin (L) as a neoadjuvant chemotherapy (CT) for patients with advanced, unresectable squamous cell carcinoma of the head and neck.
  • Otherwise, paclitaxel-PTL was continued for up to six cycles before commencement of locoregional therapy.
  • RR and CR rates for the neck lymph nodes were 85.3% (15 of 18) and 22% (4 of 18), respectively.
  • The combined RR for primary tumors and neck lymph nodes was 81% (95% confidence interval, 62.9-99.3%) with a CR rate of 19%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Female. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Salvage Therapy. Survival Rate. Tegafur / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15386306.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin
  •  go-up   go-down


3. Fouret P, Temam S, Charlotte F, Lacau-St-Guily J: Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck. Br J Cancer; 2002 Dec 2;87(12):1390-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
  • The purpose of this study was to establish the relative contribution of tumour stage, node stage, p53 gene status, p53 expression, and bcl-2 protein expression to tumour response to platin-fluorouracil chemotherapy in 141 patients with squamous-cell carcinomas of the head and neck.
  • Tumour response was measured at the primary site after three cycles of chemotherapy.
  • T1 or T2 stage (adjusted odds ratio, 3.3; 95% confidence interval 1.3-8.7; P=0.01), N0 node stage (adjusted odds ratio, 2.7; 95% confidence interval 1.1-6.4; P=0.03), p53 wild-type gene (adjusted odds ratio, 4.0; 95% confidence interval 1.7-9.5; P=0.002), and bcl-2 protein expression (adjusted odds ratio, 20; 95% confidence interval 2.3-170; P=0.006), were positively associated with tumour response.
  • In conclusion, tumour stage, node stage, p53 gene status, and bcl-2 expression are independent predictors of tumour response to platin-fluorouracil in patients with squamous-cell carcinomas of the head and neck.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Genes, p53 / genetics. Head and Neck Neoplasms / drug therapy. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Cisplatin / administration & dosage. DNA, Neoplasm / metabolism. Female. Fluorouracil / administration & dosage. Humans. Immunoenzyme Techniques. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Cancer Research UK
  • [Cites] Int J Cancer. 1993 Apr 1;53(6):952-6 [8386140.001]
  • [Cites] Int J Cancer. 1993 Jan 2;53(1):29-35 [8380056.001]
  • [Cites] N Engl J Med. 1993 Sep 2;329(10):690-4 [8393963.001]
  • [Cites] Cell. 1993 Aug 27;74(4):609-19 [8358790.001]
  • [Cites] Cell. 1993 Sep 24;74(6):957-67 [8402885.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1191-8 [7977649.001]
  • [Cites] Br J Cancer. 1995 May;71(5):1003-7 [7734290.001]
  • [Cites] Nat Med. 1995 Oct;1(10):1029-34 [7489358.001]
  • [Cites] Blood. 1996 Jan 1;87(1):265-72 [8547651.001]
  • [Cites] Am J Clin Pathol. 1996 Mar;105(3):341-9 [8602616.001]
  • [Cites] Cancer Res. 1996 Apr 15;56(8):1834-41 [8620501.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):255-64 [8625232.001]
  • [Cites] Nat Med. 1996 Jul;2(7):811-4 [8673929.001]
  • [Cites] Anticancer Res. 1996 Jul-Aug;16(4C):2403-8 [8816842.001]
  • [Cites] J Natl Cancer Inst. 1996 Nov 6;88(21):1580-6 [8901856.001]
  • [Cites] N Engl J Med. 1997 Aug 21;337(8):529-34 [9262496.001]
  • [Cites] Cancer. 1998 Jul 1;83(1):7-18 [9655287.001]
  • [Cites] Clin Cancer Res. 1995 Nov;1(11):1375-83 [9815934.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):261-7 [9816168.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):164-70 [9921989.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):801-6 [10213215.001]
  • [Cites] Nature. 1999 Jun 3;399(6735):483-7 [10365962.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):385-94 [10637254.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):485-95 [10688869.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1465-73 [10735894.001]
  • [Cites] Nat Med. 2000 Sep;6(9):1029-35 [10973324.001]
  • [Cites] Science. 1985 Jun 21;228(4706):1440-3 [3874430.001]
  • [Cites] Am J Pathol. 1990 Aug;137(2):225-32 [2201196.001]
  • [Cites] Nature. 1991 Apr 4;350(6317):427-8 [1849234.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):849-52 [8479523.001]
  • (PMID = 12454767.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2376282
  •  go-up   go-down


Advertisement
4. Muller A, Sonkoly E, Eulert C, Gerber PA, Kubitza R, Schirlau K, Franken-Kunkel P, Poremba C, Snyderman C, Klotz LO, Ruzicka T, Bier H, Zlotnik A, Whiteside TL, Homey B, Hoffmann TK: Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy. Int J Cancer; 2006 May 1;118(9):2147-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy.
  • Head and neck carcinomas are histologically and clinically heterogeneous.
  • To study cellular and molecular mechanisms of organ-specific metastasis, we used SCC and ACC cell lines and tumor tissues, obtained from patients with primary or metastatic disease.
  • SCC predominantly expressed receptors for chemokines homeostatically expressed in lymph nodes, including CC chemokine receptor (CCR) 7 and CXC chemokine receptor (CXCR)5.
  • No difference in expression of chemokine receptors was seen in primary SCC and corresponding lymph node metastases.
  • Treatment of ACC cells with CXCL12 resulted in the activation of Akt and ERK1/2 pathways.
  • Discrimination of the chemokine receptor profile in SCC and ACC in vitro and in tissues provided insights into their distinct biologic and clinical characteristics as well as indications that chemokine receptors might serve as future therapeutic targets in these malignancies.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Adenoid Cystic / secondary. Carcinoma, Squamous Cell / secondary. Cisplatin / pharmacology. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / pathology. Receptors, Chemokine / analysis
  • [MeSH-minor] Apoptosis. Cell Survival. Gene Expression Profiling. Humans. Neoplasm Metastasis. RNA, Messenger / analysis. Signal Transduction


5. Murthy R, Honavar SG, Burman S, Vemuganti GK, Naik MN, Reddy VA: Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis. Ophthal Plast Reconstr Surg; 2005 Jul;21(4):307-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis.
  • A 55-year-old Asian Indian woman who had recurrent sebaceous gland carcinoma of the left lower eyelid with orbital extension and regional lymph node metastasis was treated with neoadjuvant chemotherapy, using a combination of carboplatin and 5-fluorouracil.
  • Eyelid-sparing orbital exenteration was performed after 3 cycles of chemotherapy, followed by radiotherapy to the regional lymph nodes.
  • Subsequently, 3 cycles of adjuvant chemotherapy were administered.
  • Significant eyelid and orbital tumor volume reduction was achieved with neoadjuvant chemotherapy, making eyelid-sparing orbital exenteration possible.
  • Chemotherapy also spared the patient from radical neck dissection.
  • [MeSH-major] Adenocarcinoma, Sebaceous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Eyelid Neoplasms / drug therapy. Orbital Neoplasms / drug therapy. Sebaceous Gland Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16052148.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Pisani F, Marino M, Sentinelli S, Petti MC: Follicular dendritic cell sarcoma of the neck: report of a case treated by surgical excision and COP plus (PEG)-liposomal doxorubicin. J Exp Clin Cancer Res; 2008;27:33
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular dendritic cell sarcoma of the neck: report of a case treated by surgical excision and COP plus (PEG)-liposomal doxorubicin.
  • BACKGROUND: Follicular dendritic cell (FDC) sarcoma is a rare neoplasm arising in lymph nodes but also in extranodal sites from accessory cells of the immune system that are essential for the function of antigen presentation and germinal center reaction regulation.
  • METHODS: We report the case of a 49-year old woman patient who showed persistent, enlarged, hard, cervical lymph node.
  • Immunohistochemically, tumor cells were diffusely positive for follicular dendritic cell markers CD21, CD23 and negative for cytokeratin.The patient after complete excision of the lymph node underwent five courses of adjuvant chemotherapy with COP plus PEG-liposomal doxorubicin, considering the propensity of the tumor to metastasize.
  • CONCLUSION: These results suggest that this therapeutic modality may be useful in the management of FDC sarcoma.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Dendritic Cell Sarcoma, Follicular / therapy. Doxorubicin / therapeutic use. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Lymph Nodes / pathology. Middle Aged. Receptors, Complement 3d / immunology. Receptors, IgE / immunology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1986 Mar;122(3):562-72 [2420185.001]
  • [Cites] Tumori. 2003 May-Jun;89(3):237-49 [12908776.001]
  • [Cites] Semin Diagn Pathol. 1998 May;15(2):144-54 [9606805.001]
  • [Cites] Am J Hematol. 1998 Oct;59(2):161-7 [9766802.001]
  • [Cites] J Pak Med Assoc. 2006 Mar;56(3):137-9 [16696516.001]
  • [Cites] Virchows Arch. 2006 Aug;449(2):148-58 [16758173.001]
  • [Cites] Int J Clin Oncol. 2007 Feb;12(1):56-8 [17380443.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2290-2 [10561286.001]
  • [Cites] Histopathology. 2001 Jun;38(6):510-8 [11422494.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):50-8 [11796841.001]
  • [Cites] Histopathology. 2002 Jul;41(1):1-29 [12121233.001]
  • [Cites] Drugs. 2002;62(14):2089-126 [12269857.001]
  • [Cites] Auris Nasus Larynx. 2002 Oct;29(4):401-3 [12393051.001]
  • [Cites] Oral Oncol. 2003 Jun;39(4):415-9 [12676264.001]
  • [Cites] Clin Pharmacokinet. 2003;42(5):419-36 [12739982.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):294-313 [9010103.001]
  • (PMID = 18761751.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Receptors, Complement 3d; 0 / Receptors, IgE; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ PMC2556649
  •  go-up   go-down


7. Wu Z, Huang X, Kang F: [The neck treatment of cN0 patients with squamous cell carcinoma of buccal mucosa]. Hua Xi Kou Qiang Yi Xue Za Zhi; 2003 Jun;21(3):194-6
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The neck treatment of cN0 patients with squamous cell carcinoma of buccal mucosa].
  • OBJECTIVE: The purpose of this study was to discuss the principle in neck treatment of cN0 patients with squamous cell carcinoma of buccal mucosa.
  • All the patients received a comprehensive therapy consisting of surgical procedures combined with chemotherapy and radiotherapy.
  • The combining radical therapy of buccal, mandible and neck was the main surgical method.
  • Lymph nodes were cleared after operation and examined by pathological method.
  • RESULTS: 17 patients had lymph nodes metastasis, the occult metastasis (OM) rate was 16.83%.
  • The metastasized lymph nodes were mainly located in submandible and superior deep cervix lymph nodes, their respective metastasis rate was 41.18% and 29.41%.
  • CONCLUSION: The rate of occult metastasis of squamous cell carcinoma of buccal mucosa is high, and then we should adopt actively selective neck dissection for the cN0 patients of squamous cell carcinoma of buccal mucosa.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Lymphatic Metastasis. Mouth Neoplasms / surgery. Neck Dissection
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Mouth Mucosa / surgery. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12898760.001).
  • [ISSN] 1000-1182
  • [Journal-full-title] Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology
  • [ISO-abbreviation] Hua Xi Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Moon KS, Jung S, Lee MC, Kim IY, Kim HW, Lee JK, Kim TS: Metastatic glioblastoma in cervical lymph node after repeated craniotomies: report of a case with diagnosis by fine needle aspiration. J Korean Med Sci; 2004 Dec;19(6):911-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic glioblastoma in cervical lymph node after repeated craniotomies: report of a case with diagnosis by fine needle aspiration.
  • Head and neck metastasis from glioblastoma is rare event usually seen in patients with previous and repeated surgery.
  • We present the case of a 35 yr-old-female suffering from metastatic glioblastoma in cervical lymph node that was diagnosed by fine needle aspiration.
  • Cytological diagnosis was made by light microscopy with immunostaining with glial fibrillay acid protein.
  • Chemotherapy with vincristine and procarbazine was performed.
  • The cervical masses were decreased in size and some disappeared while the intracranial glioblastoma continued to grow during chemotherapy.
  • We discuss possible explanations for these different courses after chemotherapy in extraneural metastatic glioblastoma and primary intracranial glioblastoma.
  • [MeSH-major] Brain Neoplasms / surgery. Glioblastoma / pathology. Glioblastoma / secondary. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Craniotomy. Female. Humans. Lymphatic Metastasis. Neck. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropathology. 2003 Jun;23(2):146-9 [12777104.001]
  • [Cites] J Neurosurg. 1969 Jul;31(1):50-8 [4307543.001]
  • [Cites] Cancer. 1978 Dec;42(6):2854-64 [215298.001]
  • [Cites] Cancer. 1980 Jan 1;45(1):112-25 [6985826.001]
  • [Cites] Ann Neurol. 1980 Dec;8(6):605-8 [6260012.001]
  • [Cites] J Neurosurg. 1985 Jun;62(6):918-21 [2987441.001]
  • [Cites] W V Med J. 1998 Sep-Oct;94(5):276-8 [9803886.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):413-8 [4047352.001]
  • [Cites] Neurosurgery. 1990 Oct;27(4):516-21; discussion 521-2 [2172859.001]
  • [Cites] Acta Cytol. 1993 Nov-Dec;37(6):938-42 [8249517.001]
  • [Cites] Neurosurgery. 1995 Jan;36(1):124-32; discussion 132 [7708148.001]
  • [Cites] Diagn Cytopathol. 1996 Jul;15(1):60-5 [8807254.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Nov-Dec;17(10):1929-31 [8933881.001]
  • [Cites] Cancer. 1985 Oct 1;56(7 Suppl):1778-82 [4027909.001]
  • (PMID = 15608410.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2816292
  •  go-up   go-down


9. Rinehart J, Ruff T, Cheung A, Hutchinson L, Tuggle R, Pinkston DR, Keville L, Wong L: Neoadjuvant and concomitant chemotherapy and radiation therapy in patients with advanced head and neck carcinoma. Otolaryngol Head Neck Surg; 2005 Jan;132(1):69-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant and concomitant chemotherapy and radiation therapy in patients with advanced head and neck carcinoma.
  • Our study evaluated the effectiveness of neoadjuvant chemotherapy and concomitant chemotherapy with radiotherapy compared to standard surgery and radiation therapy in patients with resectable stage III/IV head and neck squamous cell carcinoma.
  • Forty-two eligible patients received neoadjuvant chemotherapy (cisplatin 100 mg/m2 intravenously day 1, and 5-fluorouracil 1 g/m2 /day continuous infusion days 1-5 every 3 weeks for 3 courses) followed by radiotherapy (65-70 Gy in 32-39 fractions to the primary site and lymph nodes; 50 Gy in 25-28 fractions to areas at risk) and concomitant chemotherapy (cisplatin 80 mg/m 2 intravenously every 3 weeks starting on day 1 of radiotherapy).
  • Neoadjuvant therapy induced grade 4 cytopenias (12/42 patients) and grade 4 gastrointestinal toxicities (7/42 patients).
  • Neoadjuvant chemotherapy biopsy-proven complete responses were 15 of 42 patients (36%), partial responses in 23 of 42 patients (55%), and an overall response rate of 91%.
  • The 3-year disease-free and overall survival for chemotherapy plus radiotherapy versus surgery plus radiotherapy: 61% versus 43% (P = 0.17) and 71% versus 43% (P = 0.02).
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15632912.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Kurita H, Koike T, Miyazawa H, Uehara S, Kobayashi H, Kurashina K: Retrospective analysis on prognostic impact of adjuvant chemotherapy in the patients with advanced and resectable oral squamous cell carcinoma. Gan To Kagaku Ryoho; 2006 Jul;33(7):915-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis on prognostic impact of adjuvant chemotherapy in the patients with advanced and resectable oral squamous cell carcinoma.
  • PURPOSE: The effect of adjuvant chemotherapy on oral squamous cell carcinoma (SCC) is unclear mainly because there have been a few studies which evaluate the efficacy of adjuvant chemotherapy.
  • The purpose of this retrospective study was to analyze the efficacy of adjuvant chemotherapy in the patients with advanced and resectable oral SCC.
  • The impact of multiple variables including T-classification, degree of differentiation, mode of invasion, number and level of cervical metastatic node, pre-and post-operative radiation therapy, neoadjuvant chemotherapy, and adjuvant chemotherapy on survival and control of local relapse or distant metastasis was assessed using the stepwise Cox proportional hazards model.
  • RESULTS: The level of neck node metastasis (p<0.02) was a significant independent predictor for cause-specific survival and adjuvant chemotherapy was of borderline significance (p=0.07).
  • The number of neck node metastasis (p<0.01) and adjuvant chemotherapy (p<0.01) were significantly related with disease free survival.
  • CONCLUSION: The results of this retrospective study suggested that adjuvant chemotherapy had a significant benefit in improving disease free survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Lymph Nodes / pathology. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Drug Combinations. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. Proportional Hazards Models. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Tegafur / administration & dosage. Uracil / administration & dosage


11. Gunel N, Akcali Z, Coskun U, Akyol G, Yamac D, Yenidünya S: Prognostic importance of tumor angiogenesis in breast carcinoma with adjuvant chemotherapy. Pathol Res Pract; 2002;198(1):7-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic importance of tumor angiogenesis in breast carcinoma with adjuvant chemotherapy.
  • Four patients received tamoxifen, 25 patients received CAF or CA, and 15 patients received CMF as adjuvant therapy.
  • Ten patients (43.5%) in the node-positive group and 2 patients (10.5%) in the node-negative group relapsed (p = 0.019).
  • MVCs of postmenopausal and premenopausal patients were 50.13 +/- 5.74 and 68.64 +/- 4.11, respectively, in the axillary lymph node (ALN)-negative patient group (p = 0.04).
  • Of all ALN-negative patients with increased angiogenesis, one patient of the CMF group relapsed, but no recurrence occurred in patients undergoing anthracycline-based chemotherapy (p > 0.05).
  • Despite the statistical insignificance, anthracycline-based adjuvant chemotherapy appears to be more effective than CMF as regards relapse prevention particularly in early ALN-positive breast cancer patients with increased angiogenesis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / blood supply. Breast Neoplasms / drug therapy. Neovascularization, Pathologic / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Neck. Neoplasm Staging. Postmenopause. Premenopause. Prognosis. Retrospective Studies. Survival Rate. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11866215.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


12. Resche-Rigon P, Pignon T, Giovanni A, Gras R, Bagarry D, Zanaret M: [Concomitant radiotherapy-chemotherapy for unresectable cancers of the head and neck: a retrospective analysis of 130 patients]. Ann Otolaryngol Chir Cervicofac; 2003 Feb;120(1):3-13
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concomitant radiotherapy-chemotherapy for unresectable cancers of the head and neck: a retrospective analysis of 130 patients].
  • [Transliterated title] Radiothérapie-chimiothérapie concomitante des cancers non opérables de la tête et du cou. Etude rétrospective sur 130 patients.
  • OBJECTIVES: We analyzed retrospectively the files of 130 patients with unresectable cancer of the head and neck who were given concomitant radiotherapy-chemotherapy between January 1993 and February 2000.
  • Treatment combined radiotherapy (70.2 Gy centered on the tumor with 50.4 Gy on the lymph nodes) and chemotherapy using three cycles of cisplatinium combined with 5-fluorouracil in continuous infusion for 120 hr.
  • CONCLUSION: Univariate analysis of prognostic factors points out the importance of the nutritional status before and during treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiation Dosage. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12717312.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


13. Ikushima I, Korogi Y, Ishii A, Hirai T, Yamura M, Nishimura R, Baba Y, Yamashita Y, Shinohara M: Superselective arterial infusion chemotherapy for squamous cell carcinomas of the oral cavity: histopathologic effects on metastatic neck lymph nodes. Eur Arch Otorhinolaryngol; 2007 Mar;264(3):269-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superselective arterial infusion chemotherapy for squamous cell carcinomas of the oral cavity: histopathologic effects on metastatic neck lymph nodes.
  • We have performed superselective intra-arterial infusion chemotherapy (SIC) on carcinomas of the oral cavity according to a protocol in which the distribution of the drug was evaluated by the use of a combined CT and angiography system, and the chemotherapy was combined with medium-dose conformal radiation therapy (CRT).
  • The purpose of this study was to evaluate the pathological effect of this treatment on the metastatic neck lymph nodes (LNs).
  • Twenty consecutive patients who had metastatic neck LNs from squamous cell carcinomas of the mouth and who underwent both SIC and CRT were included in this study, in which a total of 22 LNs were evaluated.
  • The total and daily doses delivered were 30 and 2.0 Gy, respectively.
  • All 23 control LNs with no treatment showed grade 0 response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Mouth Neoplasms / drug therapy. Mouth Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Infusions, Intra-Arterial. Lymphatic Metastasis / pathology. Lymphatic Metastasis / radiotherapy. Male. Middle Aged. Neck. Neoplasm Staging. Prognosis. Radiotherapy, Conformal / methods. Tongue Neoplasms / drug therapy. Tongue Neoplasms / pathology. Tongue Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1995 Nov;165(5):1269-72 [7572516.001]
  • [Cites] J Craniomaxillofac Surg. 2002 Apr;30(2):112-20 [12069515.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1987 Nov;113(11):1183-90 [3663345.001]
  • [Cites] Cancer. 1988 Mar 1;61(5):903-8 [3338055.001]
  • [Cites] Head Neck Surg. 1984 Jan-Feb;6(3):751-60 [6198307.001]
  • [Cites] Eur J Radiol. 1995 Dec 15;21(2):94-9 [8850500.001]
  • [Cites] Am J Otolaryngol. 1990 Mar-Apr;11(2):131-6 [2343996.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1989 Apr;115(4):503-11 [2466470.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Nov-Dec;21(10):1917-22 [11110547.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 May;19(5):935-41 [9613516.001]
  • [Cites] Cardiovasc Intervent Radiol. 1999 May-Jun;22(3):201-5 [10382049.001]
  • [Cites] Head Neck. 1992 Sep-Oct;14(5):364-71 [1399569.001]
  • (PMID = 17061084.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Kawashiri S, Kojima K, Kumagai S, Nakagawa K, Yamamoto E: Effects of chemotherapy on invasion and metastasis of oral cavity cancer in mice. Head Neck; 2001 Sep;23(9):764-71
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of chemotherapy on invasion and metastasis of oral cavity cancer in mice.
  • The effects of each anticancer drug and different administration timings on cancer invasion and metastasis were investigated.
  • In the control group, the tumors showed grade 4C mode of invasion, whereas in the groups treated with anticancer drugs, grade 3 was observed in 77.3% of the mice, with an inhibitory effect on tumor invasion being observed.
  • The rate of metastasis in the cervical lymph node was significantly decreased in the groups treated with the cisplatin or peplomycin on day 7 after implantation.
  • The tumor stage progression in the metastatic lymph nodes was also inhibited.
  • CONCLUSIONS: Chemotherapy is effective not only for tumor diminution but also for inhibiting invasion and metastasis.
  • In light of these effects, administration of anticancer drugs may be clinically useful in this regard.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cell Line. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Disease Models, Animal. Drug Administration Schedule. Lymphatic Metastasis. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Metastasis. Peplomycin / administration & dosage. Peplomycin / therapeutic use

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11505487.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 56H9L80NIZ / Peplomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Kovács AF, Landes CA, Hamscho N, Döbert N, Menzel C: Pattern of drainage in sentinel lymph nodes after intra-arterial chemotherapy for oral and oropharyngeal cancer. J Oral Maxillofac Surg; 2005 Feb;63(2):185-90
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of drainage in sentinel lymph nodes after intra-arterial chemotherapy for oral and oropharyngeal cancer.
  • PURPOSE: Prerequisite for lymphoscintigraphy-guided sentinel lymph node (SLN) biopsy in head and neck cancer patients has been a previously untreated primary tumor to avoid disturbance of the lymphatic flow.
  • We evaluated the feasibility in a multimodality treatment approach to oral and oropharyngeal cancer comprising presurgical intra-arterial chemotherapy of the primary tumor.
  • PATIENTS AND METHODS: In a prospective study of 35 consecutive patients with primary oral and anterior oropharyngeal cancer T1-4N0 treated with superselective intra-arterial chemotherapy with high-dose cisplatin, SLN scintigraphy was performed on the day of surgery, including gamma camera imaging before and hand-held gamma probe identification of the SLN during surgery.
  • SLN biopsy was performed in 50 neck sides, followed by radical resection of the primary in the same session.
  • Elective neck dissection was not carried out.
  • The pattern of lymphatic drainage was recorded and compared with the literature on well-known patterns found in lymphographic studies and metastatic disease in neck dissection specimens of patients without presurgical treatment.
  • After a median observation time of 24 months, no patients had a neck relapse.
  • CONCLUSIONS: The results suggest that intra-arterial chemotherapy of the primary tumor does not significantly alter lymphatic drainage and that SLN biopsy following intra-arterial chemotherapy is feasible and offers valid results comparable to those obtained from patients without presurgical treatment.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Cisplatin / administration & dosage. Mouth Neoplasms / drug therapy. Oropharyngeal Neoplasms / drug therapy. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Female. Humans. Injections, Intra-Arterial. Lymph Nodes / radionuclide imaging. Male. Neck. Neoplasm Recurrence, Local. Neoplasm Staging / methods. Prospective Studies. Radionuclide Imaging. Radiopharmaceuticals. Technetium Tc 99m Aggregated Albumin

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690286.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0 / Technetium Tc 99m Aggregated Albumin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Song CH, Wu HG, Heo DS, Kim KH, Sung MW, Park CI: Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma. Laryngoscope; 2008 Apr;118(4):663-70
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma.
  • OBJECTIVES: To analyze the impact of neoadjuvant chemotherapy (CT) on the treatment of early-stage nasopharyngeal carcinoma (NPC) as compared with radiotherapy (RT) alone.
  • RT was given to the nasopharynx and neck nodes.
  • The median dose to the primary site, involved nodes, and elective nodes was 70.2 Gy, 63 Gy, and 45 Gy, respectively.
  • CONCLUSIONS: In our retrospective analysis, the use of neoadjuvant CT showed no additional benefit to treatment with RT alone.
  • [MeSH-major] Carcinoma / radiotherapy. Nasopharyngeal Neoplasms / radiotherapy. Neoadjuvant Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Child. Cisplatin / administration & dosage. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Lymph Nodes / radiation effects. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18216741.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Wang HM, Hsueh CT, Wang CS, Chen IH, Liao CT, Tsai MH, Yeh SP, Chang JT: Phase II trial of cisplatin, tegafur plus uracil and leucovorin as neoadjuvant chemotherapy in patients with squamous cell carcinoma of the oropharynx and hypopharynx. Anticancer Drugs; 2005 Apr;16(4):447-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of cisplatin, tegafur plus uracil and leucovorin as neoadjuvant chemotherapy in patients with squamous cell carcinoma of the oropharynx and hypopharynx.
  • We evaluated the efficacy and toxicity of cisplatin, tegafur plus uracil and leucovorin as neoadjuvant chemotherapy for locally advanced squamous cell carcinoma (SCC) of the oropharynx and hypopharynx.
  • Evaluation after 3 cycles led to chemotherapy termination if primary tumor responses were less than partial responses.
  • Otherwise, PUL was continued up to 6 cycles before locoregional therapy.
  • Patients achieving at least good partial responses at the primary site after neoadjuvant chemotherapy received radiotherapy for organ preservation.
  • Chemotherapy responses were analyzed by intent-to-treat.
  • Overall response and complete response rates of neck lymph nodes were 68.6% (24 of 35) and 25.7% (nine of 35).
  • The combined response rate of primary site and neck lymph nodes was 63% (95% confidence interval 48.5-77.5%) with a complete response rate of 15.2%.
  • We concluded that the outpatient PUL regimen was a moderately effective, less-toxic neoadjuvant chemotherapy for SCC of the oropharynx and hypopharynx.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Neoadjuvant Therapy. Oropharyngeal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Female. Humans. Leucovorin / administration & dosage. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Survival Rate. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746582.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin
  •  go-up   go-down


18. Matsutani T, Sasajima K, Kobayashi Y, Suzuki S, Maruyama H, Miyamoto M, Yokoyama T, Sugiura A, Matsushita A, Yanagi K, Matsuda A, Arai H, Nishi Y, Wakabayashi H, Tajiri T: [A case of double advanced cancer with esophageal and hypopharyngeal carcinoma responding completely to combination chemotherapy of docetaxel/5-fluorouracil and nedaplatin with radiation]. Gan To Kagaku Ryoho; 2009 May;36(5):835-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of double advanced cancer with esophageal and hypopharyngeal carcinoma responding completely to combination chemotherapy of docetaxel/5-fluorouracil and nedaplatin with radiation].
  • The diagnosis was double cancer with hypopharyngeal and esophageal carcinoma from upper gastrointestinal endoscopic examination.
  • Computed tomography(CT)of the neck and abdomen showed metastases of the right neck and cardiac lymph nodes.
  • He received radiation therapy in combination with chemotherapy using docetaxel(DOC), 5-fluorouracil (5-FU)and nedaplatin(CDGP).
  • After this combination chemoradiation therapy(CRT), the adverse event was grade 2 in leucopenia and grade 2 in gastrointestinal toxicity.
  • Repeated macroscopic and histological examinations after CRT revealed disappearance of the hypopharyngeal and advanced esophageal carcinoma with lymph node metastasis, leading to a complete response(CR).
  • This combination chemotherapy of DOC, 5-FU and CDGP with radiation may well be effective and tolerable for patients with double cancer of hypopharyngeal and esophageal carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / radiotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Esophagoscopy. Fluorouracil / therapeutic use. Humans. Male. Neoplasm Staging. Organoplatinum Compounds / therapeutic use. Remission Induction. Taxoids / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461189.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 15H5577CQD / docetaxel; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Funakoshi K, Tasaki A, Inayoshi J, Arai F, Motoyama H, Akiyama N, Kato T: [A case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP]. Gan To Kagaku Ryoho; 2003 Nov;30(12):1967-71
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP].
  • We report a case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP.
  • A 52-year-old male was diagnosed with type 3 gastric cancer of angulus (poorly differentiated adenocarcinoma) with left neck, Virchow, mediastinal and abdominal lymph nodes metastases.
  • The patient was treated with 5 courses of M-FLP (MTX + 5-FU + LV + CDDP), and the effect of this therapy was PR, but the tumor was chemoresistant to the sixth course of this therapy.
  • After 7 courses of M-FLP, docetaxel (TXT) with low-dose FP (5-FU + CDDP) was administered to the patient as second-line chemotherapy.
  • After 2 courses of TXT with low-dose FP, the gastric cancer and metastatic lymph nodes were remarkably reduced and the effect of this therapy was PR.
  • CDDP and 5-FU based regimens are considered as the first-line chemotherapy for metastatic advanced gastric cancer in Japan; however, a second-line chemotherapy has not been established.
  • As in this case, a TXT based regimen is effective and well tolerated therapy as a second-line chemotherapy for metastatic gastric cancer after prior exposure to CDDP and 5-FU.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Lymphatic Metastasis. Male. Methotrexate / administration & dosage. Middle Aged. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14650969.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; M-FLP protocol
  •  go-up   go-down


20. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefèbvre JL: Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck; 2005 Oct;27(10):843-50
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).
  • BACKGROUND: In 2004, level I evidence was established for the postoperative adjuvant treatment of patients with selected high-risk locally advanced head and neck cancers, with the publication of the results of two trials conducted in Europe (European Organization Research and Treatment of Cancer; EORTC) and the United States (Radiation Therapy Oncology Group; RTOG).
  • Adjuvant chemotherapy-enhanced radiation therapy (CERT) was shown to be more efficacious than postoperative radiotherapy for these tumors in terms of locoregional control and disease-free survival.
  • However, additional studies were needed to identify precisely which patients were most suitable for such intense treatment.
  • A comparative analysis of the selection criteria, clinical and pathologic risk factors, and treatment outcomes was carried out using data pooled from these two trials.
  • There was also a trend in favor of CERT in the group of patients who had stage III-IV disease, perineural infiltration, vascular embolisms, and/or clinically enlarged level IV-V lymph nodes secondary to tumors arising in the oral cavity or oropharynx.
  • Patients who had two or more histopathologically involved lymph nodes without ECE as their only risk factor did not seem to benefit from the addition of chemotherapy in this analysis.
  • CONCLUSIONS: Subject to the usual caveats of retrospective subgroup analysis, our data suggest that in locally advanced head and neck cancer, microscopically involved resection margins and extracapsular spread of tumor from neck nodes are the most significant prognostic factors for poor outcome.
  • The addition of concomitant cisplatin to postoperative radiotherapy improves outcome in patients with one or both of these risk factors who are medically fit to receive chemotherapy.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Randomized Controlled Trials as Topic
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Risk. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc.
  • (PMID = 16161069.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10 CA11488; United States / NCI NIH HHS / CA / 5U10 CA11488-33
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Wanebo HJ, Glicksman AS, Vezeridis MP, Clark J, Tibbetts L, Koness RJ, Levy A: Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg; 2000 Jan;135(1):81-7; discussion 88
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer.
  • HYPOTHESIS: Neoadjuvant therapy has the potential to induce regression of high-risk, locally advanced cancers and render them resectable.
  • Preoperative chemoradiotherapy is proposed as a testable treatment concept for locally advanced pancreatic cancer.
  • A course of chemotherapy with fluorouracil and cisplatin plus radiotherapy was then initiated.
  • Reexploration and resection were planned subsequent to neoadjuvant therapy.
  • INTERVENTIONS: Surgically staged patients with locally advanced pancreatic cancer were treated by preoperative chemotherapy with bolus fluorouracil, 400 mg/m2, on days 1 through 3 and 28 through 30 accompanied by a 3-day infusion of cisplatin, 25 mg m2, on days 1 through 3 and 28 through 30 and concurrent radiotherapy, 45 Gy.
  • RESULTS: Of 14 patients who enrolled in the protocol and were initially surgically explored, 3 refused the second operation and 11 were reexplored; 2 showed progressive disease and were unresectable and 9 (81%) had definitive resection.
  • Pancreatic resection included standard Whipple resection in 1 patient, resection of body and neck in 1 patient, and extended resection in 6 patients (portal vein resection in 6, arterial resection in 4).
  • One patient who was considered too frail for resection had core biopsies of the pancreatic head, node dissection, and an interstitial implant of the tumorous head.
  • Lymph node downstaging occurred in 2 of 4 patients who had positive peripancreatic nodes at the initial surgical staging.
  • In the definitive surgery group the median survival was 19 months after beginning chemoradiotherapy and 16 months after definitive surgery.
  • [MeSH-major] Neoadjuvant Therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pancreas / pathology. Radiotherapy Dosage. Reoperation. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10636353.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


22. Reuther T, Posselt NK, Rabbels J, Kübler AC: [Oral squamous cell carcinoma Retrospective analysis of therapy results and prognosis by neoadjuvant, preoperative radio-chemotherapy]. Mund Kiefer Gesichtschir; 2006 Jan;10(1):18-29
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oral squamous cell carcinoma Retrospective analysis of therapy results and prognosis by neoadjuvant, preoperative radio-chemotherapy].
  • Only patients treated preoperatively with combined radio-chemotherapy (carboplatin/39.6 Gy) were included.
  • The purpose of the present study was to show the therapeutic outcome and the survival rates for this regimen.
  • Grade T4 was most the common (53.4%), and all patients were operated after preoperative treatment.
  • In 34.1% there were viable tumour cells in the cervical lymph nodes, whereas in 66.7% these cells were found in the primary tumour despite preoperative treatment.
  • The overall survival time of the disease was significantly influenced by pT (P=0.004), pN (P>0.001), R0 resections (P=0.0002), viable tumour cells in lymph node metastasis (P=0.0001), viable tumour cells in the primary (P=0.0004) and recurrence of the disease (P>0.001).
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / drug therapy. Mouth Neoplasms / radiotherapy. Neoadjuvant Therapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neck Dissection. Neoplasm Staging. Prognosis. Retrospective Studies. Surgical Flaps. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:91-3 [1639328.001]
  • [Cites] Acta Otolaryngol. 1995 Nov;115(6):833-8 [8749208.001]
  • [Cites] Int J Oral Maxillofac Surg. 1993 Apr;22(2):102-7 [8320445.001]
  • [Cites] Osterr Z Stomatol. 1983 Jun;80(6):216-27 [6583641.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:43-5 [1639309.001]
  • [Cites] Mund Kiefer Gesichtschir. 2002 Mar;6(2):91-7 [12017879.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:69-70 [1322346.001]
  • [Cites] Mund Kiefer Gesichtschir. 1998 Jan;2(1):11-3 [9522566.001]
  • [Cites] Mund Kiefer Gesichtschir. 2000 May;4 Suppl 1:S216-25 [10938662.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:26-9 [1639303.001]
  • [Cites] Strahlenther Onkol. 1989 Sep;165(9):647-51 [2678546.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:5-8 [1639312.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:33-6 [1639306.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 May;118(5):486-7 [1571117.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:108-10 [1639292.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1990;35:60-3 [1695600.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):394-7 [12076706.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:111-5 [1639293.001]
  • [Cites] JAMA. 1987 Dec 11;258(22):3286-93 [3316722.001]
  • [Cites] Plast Reconstr Surg. 1979 Sep;64(3):299-305 [382205.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:21-2 [1639300.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1968;13:30-8 [5276891.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:65-8 [1639318.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1990;35:57-60 [2373435.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:104-8 [1639291.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:13-7 [1639298.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:59-61 [1639316.001]
  • [Cites] HNO. 1993 Aug;41(8):380-4 [8407379.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Feb;52(2):149-54 [8295049.001]
  • [Cites] J Otolaryngol. 1989 Apr;18(3):105-8 [2716083.001]
  • [Cites] Zahn Mund Kieferheilkd Zentralbl. 1986;74(2):161-9 [2939663.001]
  • [Cites] Cancer. 1977 Jan;39(1):204-9 [832234.001]
  • [Cites] Dtsch Z Mund Kiefer Gesichtschir. 1988 Jul-Aug;12(4):293-302 [3240611.001]
  • [Cites] Head Neck Surg. 1986 Sep-Oct;9(1):13-8 [3623928.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:86-8 [1639326.001]
  • [Cites] Dtsch Z Mund Kiefer Gesichtschir. 1984 Jul-Aug;8(4):264-70 [6084570.001]
  • [Cites] Otolaryngol Head Neck Surg. 1998 Feb;118(2):272-5 [9482566.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:37-9 [1639307.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Apr;125(4):379-82 [10208674.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:48-50 [1639311.001]
  • [Cites] Mund Kiefer Gesichtschir. 2000 May;4 Suppl 1:S142-54 [10938654.001]
  • [Cites] J Laryngol Otol. 1966 Aug;80(8):831-8 [5945238.001]
  • [Cites] Dtsch Zahn Mund Kieferheilkd Zentralbl Gesamte. 1973 Feb;60(2):81-93 [4122694.001]
  • [Cites] Cancer. 1994 Jan 1;73(1):187-90 [8275423.001]
  • [Cites] Dtsch Z Mund Kiefer Gesichtschir. 1990 Jul-Aug;14(4):242-9 [2134647.001]
  • [Cites] Plast Reconstr Surg. 1982 Apr;69(4):591-600 [7071197.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:82-6 [1639325.001]
  • [Cites] Cancer Treat Rep. 1985 Sep;69(9):933-9 [3928158.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1994;39:5-12 [8088670.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:30-3 [1639305.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Sep;119(9):958-63 [8357596.001]
  • [Cites] Dtsch Zahnarztl Z. 1951 Nov 1;6(21):1173-80 [14936642.001]
  • [Cites] Int J Oral Maxillofac Surg. 1989 Feb;18(1):39-42 [2497209.001]
  • [Cites] Mund Kiefer Gesichtschir. 2004 Jul;8(4):217-22 [15293116.001]
  • [Cites] Mund Kiefer Gesichtschir. 1998 Mar;2(2):58-61 [9567059.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:46-7 [1639310.001]
  • [Cites] Br J Plast Surg. 1980 Apr;33(2):277-82 [6446341.001]
  • [Cites] Cancer. 1994 Nov 1;74(9 Suppl):2719-25 [7954292.001]
  • [Cites] J Am Dent Assoc. 1976 Mar;92(3):571-4 [1062459.001]
  • (PMID = 16397802.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Yang L, Chen WK, Guo ZM, Gu MF, Huang HQ, Zhang Q, Yang AK: Long-term survival of induction chemotherapy plus surgery and postoperative radiotherapy in patients with stage IV hypopharyngeal cancer. Anticancer Drugs; 2010 Oct;21(9):872-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of induction chemotherapy plus surgery and postoperative radiotherapy in patients with stage IV hypopharyngeal cancer.
  • This study was conducted to evaluate the safety, efficacy, and tolerability of induction chemotherapy plus surgery and postoperative radiotherapy in patients with stage IV hypopharyngeal cancer.
  • The patients received two to three cycles of induction chemotherapy before surgery, with cisplatin (100 mg/m(2)) by rapid intravenous (i.v.) infusion over 15-20 min on day 1, bleomycin (10 mg/m(2)) on days 1 and 5, and 5-fluorouracil (800 mg/m(2)/day) by continuous i.v. infusion on days 1 through 5, repeated every 21 days.
  • After completion of two to three courses of induction chemotherapy, 22 cases of CR (complete response) and 16 cases of PR (partial response) in the primary site were confirmed, giving an overall response rate (ORR) of 73.1% [95% confidence interval (CI), 61.1-85.2%].
  • There were 17 CRs and 19 PRs in neck lymph nodes, giving an ORR of 69.2%.
  • The combined primary tumor site and lymph node response was 17 CRs and 16 PRs, giving an ORR of 63.5% (95% CI, 50.4-76.6%).
  • The median time to progression and overall survival for all the patients were 32 months (95% CI, 7.6-56.4 months) and 36 months (95% CI, 22.3-49.7 months), respectively.
  • The estimate of time to progression and overall survival at 5 years was 24.5% (95% CI, 12.5-36.5%) and 35.9% (95% CI, 23.2-48.6%), respectively.
  • In conclusion, induction chemotherapy plus surgery and postoperative radiotherapy is a treatment modality that is tolerated with encouraging activity and survival outcome in patients with stage IV hypopharyngeal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hypopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Combined Modality Therapy. Disease Progression. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant / methods. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20836197.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. McCloskey SA, Jaggernauth W, Rigual NR, Hicks WL Jr, Popat SR, Sullivan M, Mashtare TL Jr, Khan MK, Loree TR, Singh AK: Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck. Am J Clin Oncol; 2009 Dec;32(6):587-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.
  • PURPOSE: To determine whether baseline hemoglobin level and radiation treatment interruptions predict for loco-regional failure after intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy for definitive treatment of squamous cell carcinoma of the head and neck (SCCHN).
  • METHODS: This retrospective review identified 78 consecutive patients treated with definitive concurrent chemoradiation for SCCHN.
  • Patients were treated with IMRT to 70 Gy in 35 daily fractions to the high-dose target volume and 56 Gy to the elective target volume.
  • These included: 6 primary site failures, 5 regional failures, and 4 failures in both the primary site and regional lymph nodes.
  • Only duration of radiation treatment and baseline hemoglobin levels were significant predictors of local control.
  • Loco-regional failure occurred in 6 of 13 patients (46%) with radiation treatment interruptions (>1 week) versus 9 of 65 patients (14%) completing radiation therapy without interruption (P = 0.0148).
  • CONCLUSION: Overall radiation treatment time and pretreatment hemoglobin level were significant predictors for loco-regional failure after definitive concurrent chemotherapy and IMRT for SCCHN.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Hemoglobins / metabolism. Radiotherapy Dosage. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Planning, Computer-Assisted. Retrospective Studies. Survival Rate. Treatment Failure

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581794.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins
  •  go-up   go-down


25. Relic A, Scheich M, Stapf J, Voelter C, Hoppe F, Hagen R, Pfreundner L: Salvage surgery after induction chemotherapy with paclitaxel/cisplatin and primary radiotherapy for advanced laryngeal and hypopharyngeal carcinomas. Eur Arch Otorhinolaryngol; 2009 Nov;266(11):1799-805
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery after induction chemotherapy with paclitaxel/cisplatin and primary radiotherapy for advanced laryngeal and hypopharyngeal carcinomas.
  • Induction chemotherapy followed by primary radiotherapy in responders is considered an alternative to surgery for advanced cancer of the larynx and hypopharynx (LHC).
  • Comparison of therapeutic approaches is challenging and must respect oncological and functional outcome as well as quality of life during and after treatment.
  • All patients undergoing induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy from 01/96 to 07/05 were included.
  • 28 out of 134 patients underwent salvage surgery after primary treatment with induction chemotherapy and radiotherapy for advanced LHC.
  • 15 patients had laryngectomy (LE) with neck dissection (ND), while 1 patient had lasersurgical partial laryngeal resection with ND for local recurrences.
  • Twelve patients had salvage ND for suspicion of persistent lymph node metastases.
  • Eight out of 12 patients who underwent salvage ND because of suspicious lymph nodes (66%) were free of vital tumor.
  • When metastatic disease was present in the neck (4/12), recurrences occurred in 75% during postoperative follow-up.
  • Only 2 out of 20 patients undergoing surgery for histologically proven recurrence after radiochemotherapy (10%) are actually tumor-free and alive after a mean observation time of 43.9 months.
  • ND for suspicious persistent nodal disease after radiochemotherapy can be an over-treatment.
  • In our patients, it was burdened with cervical recurrences and distant metastases in presence of histologically confirmed lymph node metastases.
  • In the light of our results, unfavourable outcome after salvage surgery must be pointed out when initially informing patients about different therapeutic options for advanced LHC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / therapeutic use. Cohort Studies. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Retrospective Studies. Taxoids / therapeutic use. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1992 Aug;102(8):934-9 [1495357.001]
  • [Cites] Otolaryngol Head Neck Surg. 1986 Sep;95(2):213-8 [3108762.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Aug;124(8):871-5 [9708712.001]
  • [Cites] Strahlenther Onkol. 2002 Jul;178(7):363-8 [12163990.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 May;132(5):526-31 [16702569.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Feb;121(2):162-5 [7840923.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Dec;126(12):1473-7 [11115285.001]
  • [Cites] Head Neck. 2007 Aug;29(8):715-9 [17274056.001]
  • [Cites] Cancer. 2005 May 15;103(10):2073-81 [15816049.001]
  • [Cites] Am J Otolaryngol. 2005 Nov-Dec;26(6):388-92 [16275407.001]
  • [Cites] Head Neck. 2002 Aug;24(8):759-65 [12203801.001]
  • [Cites] Acta Otolaryngol. 2005 Jan;125(1):91-5 [15799582.001]
  • [Cites] J Laryngol Otol. 1993 Feb;107(2):130-2 [8496645.001]
  • [Cites] Cancer. 1982 Mar 15;49(6):1297-301 [7037159.001]
  • [Cites] Am J Surg. 1996 Dec;172(6):662-4 [8988672.001]
  • [Cites] Acta Oncol. 2002;41(1):69-76 [11990522.001]
  • [Cites] Int J Clin Oncol. 2006 Dec;11(6):441-8 [17180512.001]
  • [Cites] J Laryngol Otol. 1972 Aug;86(8):785-93 [5044285.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):673-8 [3338032.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1418-23 [15050318.001]
  • [Cites] Head Neck. 2003 Oct;25(10):791-8 [12966502.001]
  • [Cites] Laryngoscope. 1980 Jun;90(6 Pt 1):930-45 [7382709.001]
  • [Cites] Laryngoscope. 2006 Jun;116(6):855-8 [16735902.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Jun;122(6):892-8 [10828805.001]
  • [Cites] Acta Otolaryngol. 2006 Dec;126(11):1225-8 [17050318.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Jul;131(1):61-8 [15243559.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1995 Dec;104(12):936-41 [7492064.001]
  • [Cites] Laryngoscope. 1988 Nov;98(11):1205-11 [3054373.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Nov;11(11):1887-93 [2414254.001]
  • [Cites] Cancer. 1982 Dec 15;50(12 ):2795-801 [6182982.001]
  • [Cites] Laryngoscope. 2006 Oct;116(10):1864-6 [17003711.001]
  • [Cites] J Laryngol Otol. 1984 Sep;98(9):905-7 [6481227.001]
  • [Cites] Head Neck. 1997 Mar;19(2):116-20 [9059868.001]
  • [Cites] Eur J Surg Oncol. 1989 Aug;15(4):350-6 [2759253.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Apr;124(4):401-6 [9559686.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1986 Apr;112(4):437-9 [3484960.001]
  • [Cites] J Surg Oncol. 1990 Apr;43(4):245-9 [2325423.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1975 Nov-Dec;84(6):833-40 [1053455.001]
  • [Cites] Head Neck. 2005 Aug;27(8):653-8 [16035097.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2006 Jun;115(6):419-24 [16805372.001]
  • [Cites] Radiother Oncol. 1984 Jun;2(1):31-6 [6505273.001]
  • [Cites] Laryngoscope. 1995 Jan;105(1):97-101 [7837923.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Apr;123(4):420-4 [9109791.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2000 Apr;25(2):146-52 [10816221.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):44-9 [12525193.001]
  • [Cites] Head Neck. 2005 Feb;27(2):101-7 [15529321.001]
  • (PMID = 19288123.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Taxoids; Q20Q21Q62J / Cisplatin; TP protocol
  •  go-up   go-down


26. McCollum AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case MA, Posner MR, Van den Abbeele AD: Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck; 2004 Oct;26(10):890-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer.
  • BACKGROUND: Conventional imaging is limited in identifying persistent disease after organ-preserving therapy for patients with advanced squamous cell carcinoma of the head and neck (SCCHN).
  • We studied the accuracy of positron emission tomography (PET) with (18)F-fluoro-2-deoxy-D-glucose (FDG-PET) in restaging disease in patients with SCCHN after they had undergone induction chemotherapy (ICT) followed by chemoradiotherapy (CRT).
  • RESULTS: After induction chemotherapy, PET imaging had a sensitivity of 100% and specificity of 65% for detecting persistent disease at the primary tumor site.
  • After ICT and CRT were completed, the sensitivity and specificity of PET imaging were 67% and 53%, respectively, for detecting occult disease in cervical lymph nodes.
  • [MeSH-major] Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / therapy. Fluorodeoxyglucose F18. Head and Neck Neoplasms / radionuclide imaging. Head and Neck Neoplasms / therapy. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymph Nodes / radionuclide imaging. Male. Middle Aged. Neck. Neoplasm Staging. Neoplasm, Residual. Radiopharmaceuticals. Radiotherapy, Adjuvant. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley Periodicals, Inc.
  • (PMID = 15390197.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


27. Altundag O, Gullu I, Altundag K, Yalcin S, Ozyar E, Cengiz M, Akyol F, Yucel T, Hosal S, Sozeri B: Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients. Head Neck; 2005 Jan;27(1):15-21
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients.
  • BACKGROUND: Induction chemotherapy with cisplatin and fluorouracil and radiotherapy is an effective alternative to surgery in patients with carcinoma of the larynx and hypopharynx who are treated for organ preservation.
  • Initially, these patients were treated with two cycles of induction chemotherapy consisting of cisplatin, 20 mg/m2/day on days 1 to 5, and 5-fluorouracil, 600 mg/m2/day by continuous infusion on days 1 to 5.
  • Patients who had a complete response to chemotherapy were treated with definitive radiotherapy; patients who had a partial response to chemotherapy were treated with chemoradiotherapy.
  • Patients with N2 or N3 positive lymph nodes underwent neck dissection after the treatment.
  • The overall response rate to induction chemotherapy was 71.1%, with a 17.8% complete response rate and 53.3% partial response rate.
  • CONCLUSION: Organ preservation, with multimodality treatment, may be achievable in some of the patients with resectable, advanced larynx or hypopharynx cancers without apparent compromise of survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Neck Dissection / methods. Neoplasm Recurrence, Local. Neoplasm, Residual / surgery. Radiotherapy, Adjuvant. Salvage Therapy. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley Periodicals, Inc.
  • (PMID = 15515158.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Ampil FL, Mills GM, Caldito G, Burton GV, Nathan CO, Aarstad RF, Lian TF, Stucker FJ, Hardin JC Jr: Induction chemotherapy followed by concomitant chemoradiation-induced regression of advanced cervical lymphadenopathy in head and neck cancer as a predictor of outcome. Otolaryngol Head Neck Surg; 2002 Jun;126(6):602-6
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy followed by concomitant chemoradiation-induced regression of advanced cervical lymphadenopathy in head and neck cancer as a predictor of outcome.
  • OBJECTIVE: We sought to determine whether induction chemotherapy followed by concomitant chemoradiation (ICCR)-induced advanced neck disease regression could predict outcome, especially the need for complete neck dissection in patients with N2-3 stage IV head and neck cancer (HNC).
  • METHODS: A retrospective study of 339 patients evaluated for treatment of stage IV HNC during the years 1988 to 1997 revealed 36 individuals with N2-3 cervical lymphadenopathy who were treated with ICCR.
  • Responses to treatment, patterns of failure, and survival rates were analyzed.
  • However, such ICCR-induced complete regression of regional tumor cannot reliably predict ultimate neck disease control.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Neoplasm Staging. Predictive Value of Tests. Prognosis. Radiation Dosage. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12087325.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Moore MG, Bhattacharyya N: Effectiveness of chemotherapy and radiotherapy in sterilizing cervical nodal disease in squamous cell carcinoma of the head and neck. Laryngoscope; 2005 Apr;115(4):570-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of chemotherapy and radiotherapy in sterilizing cervical nodal disease in squamous cell carcinoma of the head and neck.
  • OBJECTIVE: Determine effects of chemoradiotherapy on nodal disease in head and neck squamous cell carcinoma (SCCA).
  • METHODS: A series of neck dissections (ND) performed for SCCA of the head and neck was retrospectively reviewed.
  • 1) planned ND after chemoradiotherapy, 2) ND after radiotherapy alone, and 3) ND before adjuvant therapy (control group).
  • Demographic data, tumor-node-metastasis stage, and pathology were reviewed.
  • Total number of nodes recovered, number of positive nodes, and extracapsular spread (ECS) were recorded.
  • To each patient in the chemoradiotherapy group, a randomly matched dissection in the control group was identified, matching for preoperative N stage and ND type (comprehensive, supraomohyoid, or selective).
  • Comparisons were conducted for total nodes, presence of positive nodes, and ECS.
  • RESULTS: Ninety-seven NDs (N0 = 10 cases, N1 = 9, N2 = 69, and N3 = 9) were matched to control NDs without previous therapy.
  • Total nodal yield was not statistically different between chemoradiotherapy and control groups (23.5 vs. 23.0 nodes, respectively, P = .77).
  • The percent of chemoradiotherapy dissections recovered as positive nodes was 24.7% versus 68.0% of the control group (P < .001).
  • However, a significant percentage of necks contain positive nodes after therapy, meriting consideration for ND.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / therapy. Lymphatic Metastasis / prevention & control
  • [MeSH-minor] Case-Control Studies. Humans. Lymph Node Excision. Lymph Nodes / pathology. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15805860.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


30. Pavlidis N, Pentheroudakis G, Plataniotis G: Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP. Clin Transl Oncol; 2009 Jun;11(6):340-8
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP.
  • Squamous cervical cancer of unknown primary site (SQCCUP) presents in patients as neck lymph nodes involved by squamous carcinoma in the absence of identifiable primary in the head, neck or lung.
  • A standardised diagnostic work-up consisting of panendoscopy of the upper aerodigestive tract, CT of the chest/abdomen and histology supplemented by immunohistochemistry is warranted for the diagnosis.
  • The cornerstones of management are excisional biopsy or surgical extirpation of the disease followed by bilateral neck external beam radiotherapy and chemotherapy.
  • The necessity for complete surgical resection of involved neck nodes, irradiation of all head/neck mucosal sites and administration of concurrent chemotherapy is currently being debated.
  • Aggressive multimodal therapy results in longterm disease control in 50-60% of patients, though data are mainly based on retrospective cohorts.
  • Recently introduced molecular profiling platforms may provide biological classification to a primary tissue of origin as well as insights into the pathophysiology of this clinical entity.
  • [MeSH-minor] Alcoholism / epidemiology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor. Clinical Trials as Topic. Combined Modality Therapy. Diagnostic Imaging. Female. Gene Expression Profiling. Humans. Lymph Node Excision. Male. Neck. Neck Dissection. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant / methods. Risk Factors. Smoking / epidemiology. Tonsillectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2003 Sep;39(14):1990-2005 [12957453.001]
  • [Cites] Oncologist. 2007 Apr;12(4):418-25 [17470684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):55-63 [11316546.001]
  • [Cites] Radiol Clin North Am. 1989 Mar;27(2):331-51 [2645606.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 Jul;259(6):325-33 [12115082.001]
  • [Cites] Laryngoscope. 1997 Jun;107(6):759-64 [9185732.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2653-8 [16763279.001]
  • [Cites] Cancer Treat Rev. 2006 Dec;32(8):637-44 [17046164.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):2009-14 [12439171.001]
  • [Cites] Ned Tijdschr Geneeskd. 2000 Jul 8;144(28):1355-60 [10923158.001]
  • [Cites] Tumori. 1977 May-Jun;63(3):267-82 [898294.001]
  • [Cites] Head Neck. 2002 Apr;24(4):361-9 [11933178.001]
  • [Cites] Cancer. 1989 Jul 15;64(2):510-5 [2736495.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):884-90 [1495353.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):599-604 [10203278.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2641-9 [15517576.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Mar;10 (3):411-23 [6706735.001]
  • [Cites] Head Neck. 2006 Dec;28(12):1090-8 [16933316.001]
  • [Cites] Am J Surg. 1990 Oct;160(4):443-6 [2221252.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1051-8 [17716824.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):727-33 [11395241.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Mar;124(3):331-3 [11241001.001]
  • [Cites] Nucl Med Commun. 2007 May;28(5):365-71 [17414886.001]
  • [Cites] Head Neck. 1998 Dec;20(8):674-81 [9790287.001]
  • [Cites] Cancer Treat Rev. 2004 Apr;30(2):153-64 [15023433.001]
  • [Cites] Otolaryngol Head Neck Surg. 2008 Sep;139(3):429-35 [18722226.001]
  • [Cites] Head Neck. 1998 Dec;20(8):739-44 [9790297.001]
  • [Cites] Surg Gynecol Obstet. 1957 May;104(5):607-17 [13433258.001]
  • [Cites] Asian J Surg. 2002 Apr;25(2):188-93 [12376245.001]
  • [Cites] Laryngoscope. 1998 Nov;108(11 Pt 1):1605-10 [9818813.001]
  • [Cites] Semin Oncol. 2008 Jun;35(3):274-85 [18544442.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] Radiology. 1984 Sep;152(3):749-53 [6463256.001]
  • [Cites] Cancer Treat Rev. 2009 May;35(3):221-7 [19046817.001]
  • [Cites] Radiother Oncol. 2001 Jun;59(3):319-21 [11369074.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(14):2026-36 [17698346.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Jan-Feb;12(1):19-24 [1846994.001]
  • [Cites] Laryngoscope. 2007 Jul;117(7):1173-9 [17603315.001]
  • [Cites] J Nucl Med. 2003 Aug;44(8):1301-14 [12902422.001]
  • [Cites] Head Neck. 2002 Mar;24(3):236-46 [11891955.001]
  • [Cites] Semin Oncol. 1993 Jun;20(3):273-8 [8503023.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(4):743-9 [1618667.001]
  • [Cites] Br J Oral Maxillofac Surg. 2008 Jun;46(4):283-7 [18243447.001]
  • [Cites] Eur Radiol. 2009 Mar;19(3):731-44 [18925401.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):92-8 [12506176.001]
  • [Cites] Cancer. 1973 Apr;31(4):854-9 [4706050.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Ann Oncol. 2003 Aug;14(8):1306-11 [12881397.001]
  • [Cites] Head Neck. 2000 Jul;22(4):336-40 [10862015.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • [Cites] Diagn Cytopathol. 1997 Jul;17(1):70-3 [9218909.001]
  • [Cites] Radiother Oncol. 2000 May;55(2):121-9 [10799723.001]
  • [Cites] Laryngoscope. 1987 Sep;97(9):1080-4 [3626734.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 May;8(5):799-809 [18471051.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Jan;5(1):24-31 [18097454.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):709-20 [10793107.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):11-6 [10690381.001]
  • (PMID = 19531448.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 58
  •  go-up   go-down


31. Moley JF, Fialkowski EA: Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg; 2007 May;31(5):946-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sporadic MTCs frequently metastasize to cervical lymph nodes.
  • Thorough surgical extirpation of the primary tumor and nodal metastases by compartment-oriented resection has been the mainstay of treatment (level IV evidence).
  • Surgical resection of residual and recurrent disease is effective in reducing calcitonin levels and controlling complications of central neck disease (level IV evidence).
  • Radioactive iodine, external beam radiation therapy, and conventional chemotherapy have not been effective.
  • Newer systemic treatments, with agents that target abnormal RET proteins hold promise and are being tested in clinical trials for patients with metastatic disease.
  • [MeSH-major] Carcinoma, Medullary / therapy. Evidence-Based Medicine. Thyroid Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Diagnostic Imaging. Humans. Lymphatic Metastasis. Neck Dissection. Neoplasm Recurrence, Local. Neoplasm, Residual. Proto-Oncogene Proteins c-ret / drug effects. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 1995 Apr;21(2):195-7 [7720896.001]
  • [Cites] World J Surg. 2007 May;31(5):957-68 [17453286.001]
  • [Cites] Br J Cancer. 2005 Jun;92 Suppl 1:S6-13 [15928657.001]
  • [Cites] Ann Surg. 1999 Nov;230(5):697-707 [10561095.001]
  • [Cites] Int J Biol Markers. 1994;9(1):21-4 [8051432.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):133-8 [2910411.001]
  • [Cites] Surgery. 1980 Jun;87(6):616-22 [7376073.001]
  • [Cites] Mol Cancer Ther. 2004 Dec;3(12):1559-64 [15634649.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Dec;23(4):549-59 [15743023.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] Tumori. 1994 Dec 31;80(6):427-32 [7900231.001]
  • [Cites] Nucl Med Commun. 2006 Apr;27(4):359-62 [16531922.001]
  • [Cites] Future Oncol. 2005 Apr;1(2):273-81 [16555999.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):715-8 [10952773.001]
  • [Cites] Br J Cancer. 1995 Feb;71(2):363-5 [7530987.001]
  • [Cites] Surg Today. 1994;24(2):112-21 [8054788.001]
  • [Cites] Ann Surg. 1990 Oct;212(4):395-400; discussion 400-1 [2222011.001]
  • [Cites] Br J Cancer. 2001 Jun 15;84(12 ):1586-90 [11401309.001]
  • [Cites] Thyroid. 1999 Jun;9(6):579-82 [10411120.001]
  • [Cites] Ann Oncol. 1994 Oct;5(8):763-5 [7826911.001]
  • [Cites] World J Surg. 1996 Jan;20(1):88-93 [8588420.001]
  • [Cites] World J Surg. 2002 Aug;26(8):886-90 [12016469.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1245-51 [11688458.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1271-4 [15517488.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jul;91(7):2496-9 [16608897.001]
  • [Cites] J Endocrinol Invest. 2006 May;29(5):427-37 [16794366.001]
  • [Cites] Langenbecks Arch Surg. 2001 Feb;386(1):47-52 [11405089.001]
  • [Cites] J Nucl Med. 2005 Apr;46(4):620-33 [15809485.001]
  • [Cites] Surgery. 2003 Dec;134(6):890-9; discussion 899-901 [14668720.001]
  • [Cites] J Clin Endocrinol Metab. 1983 Jul;57(1):124-8 [6853671.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):154-68 [16432347.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1373-6 [11038209.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2029-34 [15634717.001]
  • [Cites] Chest. 1989 Feb;95(2 Suppl):2S-4S [2914516.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):887-95 [9637552.001]
  • [Cites] Cancer. 2000 Jul 1;89(1):202-17 [10897019.001]
  • [Cites] Surgery. 2001 Dec;130(6):1044-9 [11742336.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):372-8 [9669822.001]
  • [Cites] J Surg Oncol. 2005 Mar 1;89(3):122-9 [15719378.001]
  • [Cites] Curr Treat Options Oncol. 2005 Jul;6(4):347-54 [15967087.001]
  • [Cites] Arch Surg. 1978 Apr;113(4):368-72 [637706.001]
  • [Cites] J Intern Med. 2003 Jun;253(6):616-26 [12755957.001]
  • [Cites] J Surg Oncol. 2005 Jul 1;91(1):56-60 [15999359.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):880-7; discussion 887-8 [10363903.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 May;42(5):453-60 [7621562.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Feb;82(2):338-41 [9024213.001]
  • [Cites] Surgery. 1986 Jan;99(1):60-6 [3942001.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1073-5 [12190669.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Mar;48(3):265-73 [9578814.001]
  • [Cites] World J Surg. 1996 Sep;20(7):814-20; discussion 820-1 [8678956.001]
  • [Cites] Thyroid. 1996 Aug;6(4):305-10 [8875751.001]
  • [Cites] Surgery. 1995 Dec;118(6):1024-9; discussion 1029-30 [7491518.001]
  • [Cites] Henry Ford Hosp Med J. 1992;40(3-4):271-5 [1483874.001]
  • [Cites] World J Surg. 1998 Jul;22(7):752-6; discussion 756-7 [9606293.001]
  • [Cites] Arch Surg. 2000 Aug;135(8):895-901 [10922248.001]
  • [Cites] Surgery. 2006 Jun;139(6):806-14 [16782438.001]
  • [Cites] Ann Surg. 1997 Jun;225(6):734-40; discussion 740-3 [9230814.001]
  • [Cites] Surgery. 1993 Dec;114(6):1078-81; discussion 1081-2 [8256210.001]
  • [Cites] Surgery. 1983 Dec;94(6):995-1001 [6648816.001]
  • [Cites] Surgery. 1993 Sep;114(3):491-6 [8367802.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):163-8 [14715844.001]
  • [Cites] Indian J Cancer. 2006 Apr-Jun;43(2):75-9 [16790944.001]
  • [Cites] Surgery. 1993 Dec;114(6):1090-5; discussion 1095-6 [8256212.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):449-53 [15672437.001]
  • [Cites] Surgery. 2005 Dec;138(6):986-93; discussion 993 [16360382.001]
  • [Cites] Eur J Surg Oncol. 2005 Sep;31(7):774-7 [15925476.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1705-11 [16549819.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):535-40 [16728580.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1023-8 [12016484.001]
  • (PMID = 17426901.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human
  • [Number-of-references] 70
  •  go-up   go-down


32. Werner JA, Dünne AA: Value of neck dissection in patients with squamous cell carcinoma of unknown primary. Onkologie; 2001 Feb;24(1):16-20
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of neck dissection in patients with squamous cell carcinoma of unknown primary.
  • Lymph node metastases of cancer of an unknown primary (CUP syndrome) are responsible for 3-5% of the malignant diseases in the head and neck area.
  • More than 70% of these patients show lymph node metastases of an unknown squamous cell carcinoma.
  • The survival depends immediately on number and location of lymph node metastases.
  • For a curative approach modified radical neck dissection combined with postoperative radiation therapy with or without chemotherapy should be considered in N1-N3 lymph node status.
  • A radical neck dissection with postoperative radiation therapy should only be approved in cases of infiltration of the internal jugular vein, the accessory nerve and/or the sternocleidomastoid muscle.
  • The different prognosis of patients with upper cervical and lower cervical lymph nodes should influence the indication and the extent of a neck dissection in the contralateral N0 neck.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / secondary. Lymphatic Metastasis / pathology. Neck Dissection. Neoplasms, Unknown Primary / surgery
  • [MeSH-minor] Humans. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger GmbH, Freiburg
  • (PMID = 11441275.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 37
  •  go-up   go-down


33. Börgermann C, Schmitz KJ, Sommer S, Rübben H, Krege S: [Characterization of the EGF receptor status in penile cancer : retrospective analysis of the course of the disease in 45 patients]. Urologe A; 2009 Dec;48(12):1483-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Charakterisierung des EGF-Rezeptorstatus beim Peniskarzinom : Retrospektive Auswertung der Krankheitsverläufe von 45 Patienten.
  • INTRODUCTION: Therapeutic success in metastasized squamous cell carcinoma is poor.
  • Some entities, such as head-and-neck tumors or non-small-cell lung cancer, show an over expression of the EGF receptor.
  • In latest studies target-specific substances against the EGF receptor have already been combined with chemotherapy or radiotherapy.
  • PATIENTS AND METHODS: The analysis included 45 patients, who underwent primary or secondary treatment at the Department of Urology of the University of Essen during 1990 to 2004.
  • RESULTS: A total of 25 patients were primarily without positive lymph nodes (6 times cN0 and 19 times pN0), while 20 patients had pathologically proven lymph node metastases and 3 of them also had hematogeneous metastases.
  • Out of 42 patients with follow-up 18 are still living of whom only 3 primarily had positive lymph nodes.
  • These patients received adjuvant chemotherapy after resection.
  • Out of the remaining 15 patients, 4 primarily N0 patients developed a lymphogenic recurrence, which was also resected and 3 patients also received adjuvant chemotherapy.
  • Of these 22 patients 16 primarily had positive lymph nodes and 5 of them also had an extensive primary tumor.
  • Surgery was the treatment of choice in these cases and 10 patients also received chemotherapy.
  • Nevertheless, 15 patients developed several recurrences.
  • Distinguishing primarily node-negative and node-positive patients, the Kaplan-Meyer survival curves showed a significant difference (p<0.001).
  • CONCLUSION: Clinical data underline the prognostic value of the primary lymph node status as well as the therapeutic value of an ileoinguinal lymphadenectomy and adjuvant chemotherapy.
  • It could also be shown that inductive chemotherapy is not very successful.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / secondary. Neoplasm Proteins / analysis. Penile Neoplasms / diagnosis. Penile Neoplasms / metabolism. Receptor, Epidermal Growth Factor / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urologe A. 2008 Oct;47(10):1320-7 [18587553.001]
  • [Cites] Pathology. 1997 Aug;29(3):251-4 [9271009.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):77-85 [14701768.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):433-8 [2297633.001]
  • [Cites] J Urol. 1987 May;137(5):880-2 [3573181.001]
  • [Cites] J Urol. 1994 May;151(5):1239-43 [8158767.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):359-65 [12853775.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):247-57 [19201650.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5578-87 [16009949.001]
  • [Cites] BJU Int. 2007 Dec;100(6):1277-81 [17850372.001]
  • [Cites] J Urol. 2005 Mar;173(3):816-9 [15711276.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1980-7 [12743152.001]
  • [Cites] Acta Oncol. 1988;27(6b):823-4 [2466471.001]
  • [Cites] J Urol. 1998 Nov;160(5):1770-4 [9783949.001]
  • [Cites] Eur Urol. 1997;32(1):5-15 [9266225.001]
  • [Cites] Br J Urol. 1993 Nov;72(5 Pt 2):817-9 [8281416.001]
  • [Cites] Br J Cancer. 2006 Mar 13;94(5):631-6 [16495923.001]
  • [Cites] Urol Int. 2009;82(1):1-7 [19172088.001]
  • [Cites] Urologe A. 2006 May;45(5):609-13 [16622642.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12 ):956-65 [15573117.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7350-6 [12499279.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8646-54 [16314626.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2171-7 [17538161.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Eur Urol. 2009 Mar;55(3):546-51 [18649992.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 3;90(11):824-32 [9625170.001]
  • [Cites] Oncologist. 2004;9(1):58-67 [14755015.001]
  • (PMID = 19760386.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


34. Altumbabić H, Salkić A, Ramas A, Burgić M, Kasumović M, Brkić F: Pattern of head and neck malignant tumours in a Tuzla ENT clinic--a five year experience. Bosn J Basic Med Sci; 2008 Nov;8(4):377-80
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of head and neck malignant tumours in a Tuzla ENT clinic--a five year experience.
  • Head and neck neoplasia can affect certain fundamental functions, including eating, drinking, speaking and respiration.
  • One overriding factor in deciding on treatment policy is the tendency for head and neck malignancy to be limited to the primary site and regional lymph nodes with surgery and chemotherapy and radiotherapy.
  • The aim of the study was to analyze the occurrence of Head and Neck tumours operated at ENT clinic Tuzla, University Clinical Center Tuzla, Bosnia and Herzegovina.
  • Medical records of patients with histopathologically confirmed head and neck malignancies over a 5 year period (2003-2007) were analyzed.
  • The most common sites for head and neck malignancies were found to be in the larynx (26,1%), oral cavity (21,7%), the thyroid gland (14,64 %) and the neck (8,51%).
  • The histopathological tumour types found in this work were mostly squamous cell carcinoma (72,09%), papillary carcinoma (12,2%), while many other minor histopathological variants accounted for 13%.
  • The incidence of head and neck tumours seems to be relatively high, but without significant increase during investigated period.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19125712.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


35. Ariyoshi Y, Miyatake S, Kimura Y, Shimahara T, Kawabata S, Nagata K, Suzuki M, Maruhashi A, Ono K, Shimahara M: Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis. Oncol Rep; 2007 Oct;18(4):861-6
Hazardous Substances Data Bank. BORON COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis.
  • The purpose of this clinical trial was to evaluate the utility of boron neutron capture therapy (BNCT) using epithermal neutrons for cases of recurrent cancer in the oral cavity, which are not indicated for a conventional treatment modality.
  • We enrolled four patients with local recurrence or metastasis to the regional lymph nodes after completion of initial treatments, including surgery, chemotherapy and radiotherapy.
  • Before receiving BNCT, patients underwent 18F-p-bononophenylalanine (BPA) positron emission tomography (PET) examinations to assess the BPA accumulation ratios in tumors and normal tissues.
  • Before BNCT, that patient could not be discharged from the hospital because of eating difficulties and malaise; after treatment, he was comfortably discharged.
  • Our results suggested that BNCT is a useful treatment modality for recurrent or regionally metastasized oral cancer.
  • [MeSH-major] Boron Neutron Capture Therapy / methods. Mouth Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Neutrons
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adult. Aged. Boron Compounds / therapeutic use. Carcinoma, Mucoepidermoid / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Female. Head and Neck Neoplasms / radiotherapy. Humans. Lymphatic Metastasis / radiotherapy. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786347.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Boron Compounds
  •  go-up   go-down


36. Völker HU, Scheich M, Völter C, Schmidt M, Baier G: [Predictors of nodal metastasising in laryngeal squamous cell carcinomas as decision support for neck dissection: comprehensive analysis of literature]. Laryngorhinootologie; 2008 Jun;87(6):392-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Predictors of nodal metastasising in laryngeal squamous cell carcinomas as decision support for neck dissection: comprehensive analysis of literature].
  • [Transliterated title] Prädiktoren der nodalen Metastasierung des Larynxkarzinoms als Entscheidungshilfe bei der Neck Dissection: Literaturanalyse zur Frage zuverlässiger Parameter.
  • BACKGROUND: A subset of advanced laryngeal squamous cell carcinomas (SCC) does not metastasize in regional lymph nodes (pN0).
  • The guidelines of the German ENT-Society intend the extent of neck dissection (ND) depending on clinical stage of tumor and lymph nodes.
  • If laryngeal surgery is followed by an adjuvant radiation/chemotherapy, ND is not always necessary.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Decision Support Techniques. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / surgery. Lymphatic Metastasis / pathology. Neck Dissection
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy. Humans. Lymph Nodes / pathology. Neoplasm Staging. Predictive Value of Tests. Prognosis


37. Koscielny S: [The Merkel cell carcinoma]. Laryngorhinootologie; 2008 Mar;87(3):205-10; quiz 211
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Merkel cell carcinoma is a rare tumor of the subdermal tissue.
  • Clinically, a subcutaneous rapidly growing tumor with or without enlarged lymph nodes is seen.
  • Surgical resection of the tumor combined with neck dissection followed by radiation therapy is the current therapy of choice.
  • Different chemotherapy protocols are available for patients with distant metastasis.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Head and Neck Neoplasms / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Humans. Lymphatic Metastasis. Neck Dissection. Neoplasm Staging. Radiotherapy, Adjuvant. Skin / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18322889.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


38. Lu TX: [Advance in diagnosis and management of local recurrent nasopharyngeal carcinoma]. Ai Zheng; 2004 Feb;23(2):230-4
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advance in diagnosis and management of local recurrent nasopharyngeal carcinoma].
  • Although radiotherapy is still the first measure of management of nasopharyngeal carcinoma and the curative effect is satisfactory at present, it is hard to avoid the recurrence of local-region in nasopharynx and/or neck lymph nodes in a part of patients after active treatment.
  • Of them, the diagnosis and managements were difficult.
  • The factors of the recurrence, clinical characteristics, modern diagnosis technique and the salvage treatments of modern radiotherapy, chemotherapy, and surgery for recurrent nasopharyngeal carcinoma were introduced.
  • [MeSH-major] Nasopharyngeal Neoplasms / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14960253.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 41
  •  go-up   go-down


39. Tohnai I, Hayashi Y, Mitsudo K, Shigetomi T, Ueda M, Ishigaki T: Prognostic evaluation of preoperative thermochemoradiotherapy for N(3) cervical lymph node metastases of oral cancer. Oncology; 2002;62(3):234-40
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic evaluation of preoperative thermochemoradiotherapy for N(3) cervical lymph node metastases of oral cancer.
  • OBJECTIVE: The purpose of this study was to evaluate the clinical efficacy, histopathological efficacy, and response to preoperative thermochemoradiotherapy for N(3) cervical lymph node metastases of oral cancer.
  • METHODS: Preoperative thermochemoradiotherapy was performed in 8 patients with oral cancer and N(3) cervical lymph node metastasis.
  • These patients underwent four-weekly sessions of hyperthermia, combined with radiotherapy (40 Gy) as well as chemotherapy with cisplatin (CDDP; 100 mg/m2), all prior to surgery.
  • Radical neck dissection was performed 4 weeks after completion of preoperative thermochemoradiotherapy.
  • RESULTS: The preoperative treatment of cervical lymph node metastases yielded a partial response in 6 patients, while 2 patients demonstrated no change.
  • Of the 8 patients, 2 died (1 of lymph node metastasis and 1 had metastasis to a distant site), and 6 patients were alive at the last follow-up, with the longest postoperative disease-free survival being 63 months.
  • CONCLUSION: These results indicate that preoperative thermochemoradiotherapy is a promising modality for patients with N(3) cervical lymph node metastasis of oral cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / therapy. Cisplatin / therapeutic use. Hyperthermia, Induced. Mouth Neoplasms / therapy. Radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neck. Neck Dissection. Neoplasm Staging. Preoperative Care. Prognosis. Survival Rate


40. Schwipper V: [Malignant melanoma in the area of the head and neck]. Mund Kiefer Gesichtschir; 2000 May;4 Suppl 1:S177-86
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant melanoma in the area of the head and neck].
  • At Fachklinik Hornheide, a tumor center specializing in skin neoplasm with patients being referred from all over Germany, the number of melanoma patients treated per year has been approximately 500-550 for the past 10 years.
  • In the present study, the state-of-the-art therapy for primary melanoma and treatment of the regional lymph node system is discussed.
  • The radical treatment formerly advocated with wide tumor resection plus radical neck dissection is no longer justified for this immunogenic malignant tumor caused by endogenic as well as exogenic factors.
  • "Sentinel lymph node" imaging by means of radioactive substances for diagnosing possible melanoma metastases in adjacent lymph nodes has changed the therapeutical concept.
  • In addition to surgical resection of the tumor and neck dissection for removal of lymph nodes, adjuvant immunotherapy with interferon-alpha is capable of prolonging survival without a recurrence.
  • Palliative chemotherapy or immunotherapy are valuable options for cases with generalized melanoma.
  • Vaccination with a melanoma-associated antigen or dendritic cells is at an experimental stage and may become part of future treatment strategies.
  • [MeSH-major] Head and Neck Neoplasms / therapy. Melanoma / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10938658.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 43
  •  go-up   go-down


41. Li CQ, Guo ZM, Liu WW, Zhang Q, Yang AK, Yang L: [Clinical analysis of myoepithelial carcinoma of head and neck]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Feb;45(2):124-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of myoepithelial carcinoma of head and neck].
  • OBJECTIVE: To evaluate clinical feature, diagnosis, treatment and prognosis of myoepithelial carcinoma (MC) in the head and neck.
  • The median age at diagnosis was 37 years (range: 14 - 60 years).
  • RESULTS: All cases were operated, 4 underwent surgery alone, 2 underwent surgery plus adjuvant radiotherapy, 2 received surgery plus adjuvant chemotherapy, 3 underwent surgery plus adjuvant chemoradiation.
  • After operation, 8 cases occurred local recurrence and 4 cases occurred distance and lymph nodes metastasis.
  • There was spindle cell type in 5 cases, clear cell type, plasmacytoid cell type in 2 cases, epithelioid cell type, mixed type in 1 case.
  • The median follow-up time was 40 months.
  • AS to the last follow-up time, 8 patients died.
  • CONCLUSIONS: The characteristics of the tumor were rapidly enlarging, invading the surrounding regions, high rates of lymph node metastasis, high rates of distance metastasis.
  • Chemotherapy and radiotherapy may be effective after operation.
  • [MeSH-major] Head and Neck Neoplasms. Myoepithelioma
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398508.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


42. Ehara K, Tsutsumi K, Kinoshita Y, Ueno M, Mine S, Udagawa H: [A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1375-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU].
  • The combination chemotherapy with docetaxel/CDDP/5-FU(DCF)for head and neck squamous carcinoma(SCC) has been widely accepted.
  • It seems quite natural that DCF therapy is expected to be equally effective against esophageal SCC because of their histological similarity.
  • In this report, we present a case of unresectable advanced esophageal SCC with multiple liver metastases which showed remarkable regression by DCF therapy, with relatively slight adverse effects.
  • Abdominal CT scan showed multiple liver metastases with para-aortic lymph node involvement.
  • The clinical stage diagnosis was T3N4M1, Stage IVB, obviously non-resectable far-advanced esophageal SCC.
  • Systemic chemotherapy with DCF was started as the initial treatment.
  • The chemotherapy regimen was as follows.
  • Each course was followed by a 23-day drug-free period, and the entire course was repeated every 28 days.
  • Ten cycles of this DCF chemotherapy were carried out.
  • After 8 cycles, the liver metastases were judged as CR and para-aortic lymph nodes showed a partial response(PR)by CT scan.
  • Until this writing, we added 2 more cycles of DCF therapy for the recurrent para-aortic and inguinal lymph node metastasis.
  • We conclude that DCF therapy is potentially very effective for advanced esophageal SCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology. Fluorouracil / therapeutic use. Liver Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Biomarkers, Tumor / blood. Esophagoscopes. Female. Humans. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed


43. Preś K, Pośpiech L, Krecicki T, Nadolska B, Kubacka M, Zatoński T, Jabłonka A, Piechnik-Resler D, Jankowska-Konsur A: [Malignant neoplasm of nose and paranasal sinuses in Lower Silesia in years 1992-2001]. Wiad Lek; 2006;59(11-12):797-800
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant neoplasm of nose and paranasal sinuses in Lower Silesia in years 1992-2001].
  • Malignant neoplasms of the nose and paranasal sinuses occur rarely but due to late diagnosis and poor treatment effects still remain a serious problem.
  • Principal management was combined therapy--surgery with radiotherapy in 84% of the cases.
  • Radiotherapy alone was performed in 8.8% and chemotherapy as palliative treatment in 7.1%.
  • Fifteen patients (8.2%) underwent radical neck dissection followed by radiotherapy.
  • Enlarged lymph nodes were diagnosed in 8.2%.
  • CONCLUSIONS: Unsatisfactory results of treatment are an effect of a high advanced stage of the tumor while diagnosed.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / therapy. Nose Neoplasms / epidemiology. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / epidemiology. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Neoplasm Staging / classification. Nose. Poland / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Sex Distribution. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427494.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


44. Nayak LM, Deschler DG: Lymphomas. Otolaryngol Clin North Am; 2003 Aug;36(4):625-46
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hodgkin's and non-Hodgkin's lymphomas are an important part of the differential diagnosis of head and neck tumors.
  • Their diagnosis begins with a complete history and physical examination and is confirmed with an appropriately obtained and prepared pathologic specimen.
  • Prognosis and therapy of the lymphomas vary depending on stage and the characteristics of each particular subtype of lymphoma.
  • Low-grade lymphomas and chronic lymphocytic leukemia are characterized by long survival times and are most often treated with palliative intent.
  • Although chemotherapy and radiotherapy remain the mainstays of treatment, immunotherapy demonstrates increasing promise.
  • [MeSH-major] Head and Neck Neoplasms. Lymphoma
  • [MeSH-minor] Hodgkin Disease / pathology. Hodgkin Disease / therapy. Humans. Lymph Nodes / pathology. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Lymphoproliferative Disorders / diagnosis. Magnetic Resonance Imaging. Neoplasm Staging. Prognosis. Reed-Sternberg Cells / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14567057.001).
  • [ISSN] 0030-6665
  • [Journal-full-title] Otolaryngologic clinics of North America
  • [ISO-abbreviation] Otolaryngol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 86
  •  go-up   go-down


45. Yi W, Liu XM, Xia YF, Liu Q, Li JT: [Influence of level-Ib lymphadenopathy on the prognosis of nasopharyngeal carcinoma]. Chin J Cancer; 2010 Jan;29(1):87-93
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVE: The level-Ib lymph node metastasis is rare in nasopharyngeal carcinoma (NPC).
  • METHODS: From January 1990 and December 1999, 933 newly diagnosed patients with NPC treated at Sun Yat-sen University Cancer Center were randomly selected, examined with computed tomography (CT) imagining for evidence of level-Ib lymphadenopathy before treatment.
  • All patients received radical radiotherapy with or without chemotherapy.
  • The relationship between level-Ib lymphadenopathy and post-treatment outcomes including overall survival (OS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were analyzed using Kaplan-Meier methods.
  • RESULTS: Of the 933 patients, 55 (5.9%) were found to have level-Ib lymphadenopathy, which was associated with carotid sheath involvement, oropharynx involvement and levels, and lateral cervical lymph node involvement.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Lymph Nodes / pathology. Nasopharyngeal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Child. Cobalt Radioisotopes / therapeutic use. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck / pathology. Neoplasm Metastasis. Neoplasm Recurrence, Local. Particle Accelerators. Pharynx / pathology. Prognosis. Proportional Hazards Models. Radioisotope Teletherapy. Retrospective Studies. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038317.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes
  •  go-up   go-down


51. Kovács AF, Landes CA, Hamscho N, Risse JH, Berner U, Menzel C: Sentinel node biopsy as staging tool in a multimodality treatment approach to cancer of the oral cavity and the oropharynx. Otolaryngol Head Neck Surg; 2005 Apr;132(4):570-6
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node biopsy as staging tool in a multimodality treatment approach to cancer of the oral cavity and the oropharynx.
  • OBJECTIVES: Feasibility of sentinel lymph node (SLN) biopsy in head and neck cancer as a staging tool embedded in a multimodality regimen including neoadjuvant intraarterial chemotherapy.
  • Selective SLN biopsy without elective neck dissection (ND) was performed, immediately followed by radical resection of the primary tumor.
  • Histology was positive in 3 patients (8%), all underwent ND which yielded another positive node in 2 cases.
  • Median observation time was 30 months.
  • Two patients (5%) had a neck relapse in combination with a second primary.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Mouth Neoplasms / pathology. Oropharyngeal Neoplasms / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Feasibility Studies. Female. Humans. Image Processing, Computer-Assisted. Lymph Nodes / pathology. Lymph Nodes / radionuclide imaging. Lymphatic Metastasis / pathology. Lymphatic Metastasis / radionuclide imaging. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / radionuclide imaging. Neoplasms, Second Primary / therapy. Positron-Emission Tomography. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15806047.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Oxford LE, Ducic Y: Elective transcervical superior mediastinal lymph node dissection for advanced laryngeal and level 4 N3 squamous cell carcinoma. Laryngoscope; 2005 Apr;115(4):625-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elective transcervical superior mediastinal lymph node dissection for advanced laryngeal and level 4 N3 squamous cell carcinoma.
  • OBJECTIVES: To review our results with elective superior mediastinal lymph node dissections in patients with advanced laryngeal squamous cell carcinoma (SCCA) and overt level 4 adenopathy.
  • Charts were reviewed for demographic information, prior treatment with chemotherapy or radiotherapy, and pathologic results.
  • RESULTS: Fifty-six patients who underwent elective superior mediastinal lymph node dissection for advanced laryngeal SCCA and overt level 4 adenopathy were reviewed, and superior mediastinal disease was present in 15 of 56 (26.8%) patients.
  • Superior mediastinal nodes were positive in 11 of 42 (26.2%) patients with advanced laryngeal SCCA and 4 of 14 (28.6%) patients with N3 SCCA involving level 4.
  • Patients with SCCA receiving prior chemotherapy and radiotherapy had a significantly higher rate of positive superior mediastinal nodes (10/21 patients, 47.6%) compared with patients without prior therapy (5/35 patients, 14.3%, P = .01, Fisher's exact test).
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / surgery. Lymph Node Excision / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Elective Surgical Procedures. Female. Follow-Up Studies. Humans. Lymphatic Metastasis / pathology. Male. Mediastinum. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15805871.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


53. Frikha M, Toumi N, Ghorbel L, Ben Salah H, Khabir A, Karray H, Gargouri R, Boudawara T, Ghorbel A, Daoud J: [Pediatric nasopharyngeal carcinoma: Anatomoclinic aspects, therapeutic results and evolutive particularities]. Cancer Radiother; 2010 Jun;14(3):169-75
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pediatric nasopharyngeal carcinoma: Anatomoclinic aspects, therapeutic results and evolutive particularities].
  • [Transliterated title] Le cancer du cavum de l'enfant et l'adulte jeune : aspects anatomocliniques, thérapeutiques et particularités évolutives.
  • PURPOSE: We retrospectively analyzed anatomoclinic, therapeutic and evolutive particularities of 74 young patients (< or =20 years) with nasopharyngeal carcinoma treated between 1993 and 2005.
  • PATIENTS AND METHODS: Initial work-up included a fiberoptic nasofibroscopy with biopsy, tomodensitometry and/or MRI of nasopharynx and neck, chest X-ray, abdominal ultrasonography and bone scan.
  • Patients were treated with either primary chemotherapy (epirubicin and cisplatin) followed by radiotherapy or concomitant radiochemotherapy (five fluorouracil and cisplatin).
  • Radiotherapy was delivered to a total dose of 70 to 75 Gy to nasopharynx and involved cervical lymph nodes and 50 Gy to the remainder cervical areas.
  • With a median follow-up of 107 months, one patient presented a local relapse, 24 patients developed distant metastases with a median delay of 7 months.
  • New techniques of radiotherapy and new molecules of chemotherapy could improve these results.
  • [MeSH-major] Carcinoma / epidemiology. Cobalt Radioisotopes / therapeutic use. Nasopharyngeal Neoplasms / epidemiology. Radioisotope Teletherapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Child. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / etiology. Radiotherapy, Conformal. Retrospective Studies. Treatment Outcome. Xerostomia / epidemiology. Xerostomia / etiology. Young Adult

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010. Published by Elsevier SAS.
  • (PMID = 20347607.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


54. Takizawa K, Matsuda T, Kozu T, Eguchi T, Kato H, Nakanishi Y, Hijikata A, Saito D: Lymph node staging in esophageal squamous cell carcinoma: a comparative study of endoscopic ultrasonography versus computed tomography. J Gastroenterol Hepatol; 2009 Oct;24(10):1687-91
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node staging in esophageal squamous cell carcinoma: a comparative study of endoscopic ultrasonography versus computed tomography.
  • However, only a few published studies have attempted to correlate the station of the abnormal lymph nodes detected by EUS with the definitive histology.
  • We compared EUS and computed tomography (CT) in the initial staging of esophageal squamous cell carcinoma.
  • Lymph node locations were divided into three groups; abdominal (A), paraesophageal (B), and thoracic paratracheal (C).
  • RESULTS: A total of 365 consecutive patients underwent EUS and 159 patients underwent esophagectomy without neoadjuvant chemotherapy.
  • CONCLUSIONS: This study has demonstrated that EUS is a more accurate technique than contrast-enhanced CT for detecting abnormal lymph nodes.
  • But some metastatic lymph nodes in neck and abdominal fields are only detectable by CT.
  • Therefore, both EUS and CT should be undertaken for routine examination prior to treatment of esophageal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Endosonography. Esophageal Neoplasms / secondary. Lymph Nodes / radiography. Lymph Nodes / ultrasonography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Esophagectomy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19788609.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


55. Wei WI, Mok VW: The management of neck metastases in nasopharyngeal cancer. Curr Opin Otolaryngol Head Neck Surg; 2007 Apr;15(2):99-102
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of neck metastases in nasopharyngeal cancer.
  • PURPOSE OF REVIEW: The management of cervical lymph node metastases in nasopharyngeal carcinoma is important for a favourable outcome.
  • The strategy of diagnosis and treatment for the lymph nodes on presentation and those that have recurred after initial therapy are different.
  • RECENT FINDINGS: The detection of the cervical lymph node metastases on presentation has improved with magnetic resonance imaging and positron emission tomography.
  • For those lymph nodes that have recurred after concurrent radiotherapy and chemotherapy, the progression of the nodes detected through clinical examination and imaging studies indicates that salvage therapy is necessary.
  • The surgical procedure of salvage is radical neck dissection, as pathological studies have shown that these lymph nodes exhibit extensive involvement of the neck tissue.
  • SUMMARY: Identification of lymph node metastasis provides accurate staging of the disease and radical surgery should be performed for salvage.
  • [MeSH-minor] Humans. Lymphatic Metastasis. Neoplasm Recurrence, Local / therapy. Neoplasm, Residual

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17413410.001).
  • [ISSN] 1068-9508
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


56. Veness MJ, Porceddu S, Palme CE, Morgan GJ: Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes. Head Neck; 2007 Jul;29(7):621-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes.
  • In most patients, local treatment is curative.
  • However, a subset of patients will be diagnosed with a high-risk cutaneous squamous cell carcinoma (SCC) and are defined as patients at increased risk of developing metastases to regional lymph nodes.
  • Most cutaneous SCC arises on the sun-exposed head and neck.
  • The parotid and upper cervical nodes are common sites for the development of metastases arising from ear, anterior scalp, temple/forehead, or scalp SCC.
  • Research aimed at improving outcome such as a randomized trial incorporating the addition of chemotherapy to adjuvant radiotherapy is currently in progress in Australia and New Zealand.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology. Lymph Nodes / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Humans. Immunocompromised Host. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Staging. Parotid Gland / pathology. Parotid Gland / surgery. Prognosis. Radiotherapy, Adjuvant. Sentinel Lymph Node Biopsy


57. Mack MG, Rieger J, Baghi M, Bisdas S, Vogl TJ: Cervical lymph nodes. Eur J Radiol; 2008 Jun;66(3):493-500
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical lymph nodes.
  • The lymph node staging is a very important prognostic parameter for patients with presenting with head neck cancer and is influencing the selection of the different therapeutic strategies including surgery, chemotherapy, radiotherapy or a combination of them.
  • The accuracy of imaging techniques, such as US, MR imaging, and CT, depends on the appropriateness of radiological criteria used for diagnosing lymph node metastases.
  • Size of nodes and evidence of necrosis are still the most important radiological criteria.
  • A spherical lymph node larger than 10mm is an indicator for a malignant node, whereas an oval shape and/or a fatty hilus are more benign signs.
  • But there are many limitations and different cut offs published in the literature, indicating that the size of a lymph node is not a reliable criteria for the assessment of lymph nodes in the head and neck region.
  • Today new high-resolution MRI sequences and the development of specific contrast agents are offering new possibilities in the diagnostic work-up of head and neck lymph nodes.
  • Ultrasmall superparamagnetic iron oxide particles (USPIO's) are resulting after intravenous application in a reduction of the T2 relaxation time.
  • This is causing a signal decrease on T2-weighted MR images in benign lymph nodes after administration of USPIO's, whereas malignant lymph nodes do not show a significant signal decrease.
  • Based on the fact, that the size evaluation of lymph nodes in the head and neck has not changed during the last decade, this paper will mainly focus on MRI with new contrast agents and new techniques as diffusion weighted imaging (DWI).
  • [MeSH-major] Diagnostic Imaging. Head and Neck Neoplasms / pathology. Lymphatic Metastasis / diagnosis
  • [MeSH-minor] Contrast Media. Dextrans. Ferrosoferric Oxide. Humans. Iron. Lymph Nodes / pathology. Magnetite Nanoparticles. Neoplasm Invasiveness / diagnosis. Neoplasm Staging. Oxides. Prognosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. Ferumoxides .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18337039.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Magnetite Nanoparticles; 0 / Oxides; E1UOL152H7 / Iron; G6N3J05W84 / ferumoxides; K3R6ZDH4DU / Dextrans; XM0M87F357 / Ferrosoferric Oxide
  • [Number-of-references] 45
  •  go-up   go-down


58. Asakura H, Takashima H, Mitani M, Haba R, Seo R, Yokoe K, Toyama Y, Ohkawa M: Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine. Int J Clin Oncol; 2005 Aug;10(4):285-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Occult breast cancer presenting with axillary lymph node metastases is uncommon, and inflammatory breast cancer (IBC), as a subtype, is quite rare.
  • Here we describe a case of IBC, which arose as an unknown primary carcinoma; the patient presented with axillary lymph node metastasis, and was successfully treated with trastuzumab and vinorelbine.
  • Axillary lymph node dissection was performed, and the lesion was diagnosed as a poorly differentiated adenocarcinoma.
  • About 6 months later, she was referred to our hospital, due to marked bilateral neck and axillary lymph node swelling.
  • Computed tomography (CT) of the breast showed skin thickening and swelling of the right breast.F-18 Fluorodeoxyglucose positron emission tomography (FDG-PET) showed FDG uptake in the right breast.
  • Because overexpression of the human epidermal growth factor receptor 2 (HER2) was found in the specimen from her right axillary lymph node, she was treated with trastuzumab and vinorelbine.
  • Two months after the start of chemotherapy, CT revealed a complete response in the lymph nodes, and the skin thickening and parenchymal edema of the right breast had improved.
  • FDG-PET was also performed at this time, and revealed no FDG uptake in either the right breast or the lymph nodes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / diagnosis. Breast Neoplasms / drug therapy. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / drug therapy. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Axilla. Female. Fluorodeoxyglucose F18. Humans. Lymphatic Diseases. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Staging. Radiopharmaceuticals. Receptor, ErbB-2 / metabolism. Tomography, Emission-Computed. Trastuzumab. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2003 Sep;39(14):1990-2005 [12957453.001]
  • [Cites] Arch Surg. 1990 Feb;125(2):210-4 [2302061.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):719-26 [11821453.001]
  • [Cites] Lancet. 2002 Sep 7;360(9335):790-2 [12241842.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Breast J. 2001 Nov-Dec;7(6):398-404 [11843851.001]
  • [Cites] Cancer Res. 1990 Jan 15;50(2):421-5 [1967224.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2241-51 [10327070.001]
  • [Cites] Oncogene. 1989 Oct;4(10):1233-9 [2571966.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2889-95 [12885806.001]
  • [Cites] Surg Oncol. 1999 Jul;8(1):27-33 [10885391.001]
  • [Cites] Oncologist. 2003;8(2):141-8 [12697939.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3857-62 [12473600.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Cancer. 1990 Oct 1;66(7):1461-7 [2207996.001]
  • [Cites] Gan To Kagaku Ryoho. 1995 Nov;22(13):1933-9 [7487123.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):46-53 [12506169.001]
  • (PMID = 16136377.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 5V9KLZ54CY / Vinblastine; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; Q6C979R91Y / vinorelbine
  •  go-up   go-down


59. Chen SC, Chen MF, Hwang TL, Chao TC, Lo YF, Hsueh S, Chang JT, Leung WM: Prediction of supraclavicular lymph node metastasis in breast carcinoma. Int J Radiat Oncol Biol Phys; 2002 Mar 1;52(3):614-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of supraclavicular lymph node metastasis in breast carcinoma.
  • PURPOSE: Supraclavicular lymph node metastasis in breast cancer patients has a poor prognosis, and aggressive local treatment has usually resulted in severe morbidity.
  • The purpose of this study was to select high-risk neck metastasis patients for prophylactic radiotherapy.
  • METHODS: Between 1990 and 1998, 2658 consecutive invasive breast cancer patients underwent surgery and adjuvant therapy in the hospital.
  • The following factors were analyzed: age, tumor size, tumor location, histologic type, histologic grade, estrogen and progesterone receptor status, DNA flow cytometry study results, number of positive axillary lymph nodes, use of chemotherapy, radiotherapy, and/or hormonal therapy, and level of involved axillary nodes.
  • RESULTS: Of the 2658 patients, 113 (4.3%) developed supraclavicular lymph node metastasis during this period.
  • Young age (< or =40 years), tumor size >3 cm, high histologic grade, angiolymphatic invasion, negative estrogen receptor status, synthetic phase fraction >4%, >4 positive nodes, and level II or III involved nodes were all significant for predicting neck metastasis in the univariate analysis.
  • Three predictive factors were significant after multivariate analysis: high histologic grade, >4 positive nodes, and axillary level II or III involved nodes.
  • In patients with axillary level I involved nodes and < or =4 positive nodes, the incidence was 4.4%.
  • If axillary level III was involved, the rate of supraclavicular lymph node metastasis was 15.1%.
  • CONCLUSION: The incidence of supraclavicular lymph node metastasis was higher in the groups with >4 positive nodes and in those with axillary level II or III involved nodes.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Axilla. DNA, Neoplasm / analysis. Female. Flow Cytometry. Follow-Up Studies. Humans. Lymph Nodes / pathology. Middle Aged. Neoplasm Staging. Prognosis. Recurrence. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11849781.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


60. Le QT, Koong A, Lieskovsky YY, Narasimhan B, Graves E, Pinto H, Brown JM, Spielman D: In vivo 1H magnetic resonance spectroscopy of lactate in patients with stage IV head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys; 2008 Jul 15;71(4):1151-7
Hazardous Substances Data Bank. LACTIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo 1H magnetic resonance spectroscopy of lactate in patients with stage IV head and neck squamous cell carcinoma.
  • PURPOSE: To investigate in vivo(1)H magnetic resonance spectroscopy imaging of lactate for assessing tumor hypoxia in head and neck cancers and to determine its utility in predicting the response and outcomes.
  • METHODS AND MATERIALS: Volume-localized lactate-edited (1)H magnetic resonance spectroscopy at 1.5 T was performed in vivo on involved neck nodes and control subcutaneous tissues in 36 patients with Stage IV head and neck cancer.
  • The tumor partial pressure of oxygen (pO(2)) was obtained in the same lymph node before MRS.
  • Patients were treated with either two cycles of induction chemotherapy (tirapazamine, cisplatin, 5-fluorouracil) followed by simultaneous chemoradiotherapy or the same regimen without tirapazamine.
  • RESULTS: The lactate SI was greater for the involved nodes (median, 0.25) than for the subcutaneous tissue (median, 0.04; p = 0.07).
  • No significant correlation was found between the lactate SI and tumor pO(2) (mean, 0.46 +/- 0.10 for hypoxic nodes [pO(2) < or =10 mm Hg, n = 15] vs. 0.36 +/- 0.07 for nonhypoxic nodes [pO(2) >10 mm Hg, n = 21], p = 0.44).
  • A significant correlation was found between the choline/creatine ratios and tumor pO(2) (mean, 2.74 +/- 0.34 for hypoxic nodes vs. 1.78 +/- 0.31 for nonhypoxic nodes, p = 0.02).
  • CONCLUSIONS: The lactate SI did not correlate with tumor pO(2), treatment response, or locoregional control.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2000 Jan;21(1):183-93 [10669248.001]
  • [Cites] J Magn Reson Imaging. 2007 May;25(5):992-9 [17410583.001]
  • [Cites] Neuroradiology. 2000 May;42(5):333-8 [10872152.001]
  • [Cites] Radiother Oncol. 2000 Oct;57(1):31-7 [11033186.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):349-53 [11567808.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1271-6 [11955739.001]
  • [Cites] Technol Cancer Res Treat. 2002 Feb;1(1):17-28 [12614173.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4287-95 [14555497.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Mar;120(3):283-7 [8123237.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4757-9 [7585499.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):941-3 [8640781.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):409-15 [9033256.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Jun-Jul;18(6):1057-72 [9194433.001]
  • [Cites] Neuroradiology. 1998 Feb;40(2):121-5 [9541923.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Sep;26(8):2108-13 [16155166.001]
  • [Cites] Radiother Oncol. 2005 Oct;77(1):18-24 [16098619.001]
  • [Cites] Cancer. 2006 May 1;106(9):1940-9 [16532436.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2098-104 [16648512.001]
  • [Cites] J Magn Reson Imaging. 2006 Sep;24(3):459-77 [16897689.001]
  • [Cites] Br J Radiol. 2006 Sep;79 Spec No 1:S16-26 [16980681.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5435-41 [17000677.001]
  • [Cites] Am J Clin Oncol. 2006 Dec;29(6):628-33 [17149002.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):916-21 [10706105.001]
  • (PMID = 18258377.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118582-03; United States / NCI NIH HHS / CA / P01 CA067166; United States / NCI NIH HHS / CA / P01 CA067166-120013; United States / NCI NIH HHS / CA / CA118582-03; United States / NCI NIH HHS / CA / CA-67166; United States / NCI NIH HHS / CA / CA067166-120013; United States / NCI NIH HHS / CA / 1 R01 CA118582-01; United States / NCI NIH HHS / CA / R01 CA118582
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons; 33X04XA5AT / Lactic Acid
  • [Other-IDs] NLM/ NIHMS56580; NLM/ PMC2601688
  •  go-up   go-down


61. Xie FY, Qi SN, Hu WH, Zou GR, Peng M, Li JS: [Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma]. Ai Zheng; 2007 Aug;26(8):880-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Docetaxel and cisplatin (DDP) are effective drugs for head and neck tumors.
  • Stage II-III clinical trial of TP regimen (docetaxel combined DDP) for head and neck tumors has completed.
  • RESULTS: The mean number of chemotherapy cycles was significantly higher in TP group than in PF group (3.85 cycles vs. 2.75 cycles, P<0.001).
  • After induction chemotherapy, in TP group, 18 achieved partial remission (PR) and 2 had stable disease (SD) for nasopharyngeal lesions, 7 achieved complete remission (CR), 11 achieved PR and 2 had SD for regional lymph nodes; in PF group, 17 achieved PR and 3 had SD for nasopharyngeal lesions, 2 achieved CR, 15 achieved PR and 1 had SD for regional lymph nodes.
  • After concurrent chemoradiotherapy, all in TP group and 18 in PF group achieved CR for nasopharyngeal lesions, and 19 in TP group and 15 in PF group achieved CR for regional lymph nodes.
  • The occurrence rates of grade 3-4 neutropenia were significantly higher in TP group than in PF group (40.5% vs. 0% after induction chemotherapy, 40.5% vs. 10.2% after concurrent radiochemotherapy, P<0.05).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Nasopharyngeal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Anemia / chemically induced. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Leukopenia / chemically induced. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Particle Accelerators. Radiotherapy, High-Energy / adverse effects. Stomatitis / etiology. Taxoids / administration & dosage. Taxoids / adverse effects

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697552.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


62. Healy C, Abuzakouk M, Feighery C, Flint S: Acquired angioedema in non-Hodgkin's lymphoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 May;103(5):e29-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper describes a middle-aged patient who developed repeated episodes of swelling of the orofacial tissues after dental treatment.
  • On investigation, C1 inhibitor, C1q, C2, and C4 levels were all markedly reduced, and a diagnosis of acquired C1 inhibitor deficiency was made.
  • The patient had been diagnosed with non-Hodgkin's lymphoma (NHL) 2 years previously and had undergone a successful course of chemotherapy.
  • The patient underwent a further course of chemotherapy and remains well, although C1 inhibitor, C1q, C2, and C4 levels remain reduced.
  • [MeSH-minor] Axilla. Complement C1 Inhibitor Protein / analysis. Complement C1q / analysis. Complement C2 / analysis. Complement C4 / analysis. Complement Pathway, Classical. Face. Female. Humans. Immunoglobulin Light Chains / chemistry. Lymph Nodes. Middle Aged. Neck. Neoplasm Recurrence, Local. Paraproteinemias / blood

  • Genetic Alliance. consumer health - Acquired Angioedema.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317233.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Complement C1 Inhibitor Protein; 0 / Complement C2; 0 / Complement C4; 0 / Immunoglobulin Light Chains; 80295-33-6 / Complement C1q
  •  go-up   go-down


63. Boswell JS, Flam MS, Tashjian DN, Tschang TP: Basal cell carcinoma metastatic to cervical lymph nodes and lungs. Dermatol Online J; 2006;12(6):9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma metastatic to cervical lymph nodes and lungs.
  • Metastatic basal cell carcinoma (MBCC) of the skin is rare in occurrence and may initially elude proper diagnosis and management.
  • We describe a case of MBCC to cervical lymph nodes, originally evaluated and treated surgically as metastatic thyroid carcinoma.
  • After definitive diagnosis of MBCC was made, chemotherapy and concomitant radiation treatment were initiated; however, despite these measures, the patient then developed MBCC to the lung.
  • Risk factors and current therapeutic modalities for MBCC are also discussed.
  • In addition to the more commonly metastasizing carcinomas, metastases from a cutaneous basal cell carcinoma primary tumor should be considered when evaluating cervical lymph node metastases of an uncertain head and neck primary.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Carcinoma, Papillary / diagnosis. Diagnostic Errors. Head and Neck Neoplasms / diagnosis. Lung Neoplasms / secondary. Lymphatic Metastasis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Fine-Needle. Carboplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Male. Middle Aged. Neck Dissection. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Second Primary. Radiotherapy. Seminoma. Skin Neoplasms / surgery. Taxoids / administration & dosage. Testicular Neoplasms. Thyroidectomy. Unnecessary Procedures

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083889.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


64. Chen SC, Chang HK, Lin YC, Leung WM, Tsai CS, Cheung YC, Hsueh S, See LC, Chen MF: Prognosis of breast cancer after supraclavicular lymph node metastasis: not a distant metastasis. Ann Surg Oncol; 2006 Nov;13(11):1457-65
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of breast cancer after supraclavicular lymph node metastasis: not a distant metastasis.
  • BACKGROUND: We performed this study to analyze the survival of breast cancer patients with isolated supraclavicular lymph node metastasis (SLNM) and assess whether SLNM is distant metastasis or not.
  • METHODS: Sixty-three patients who developed an isolated SLNM among 3170 primary breast cancer patients between 1990 and 1999 were enrolled.
  • The survival after SLNM was compared with that of 151 patients who developed local recurrences and 599 who had distant metastasis and was analyzed according to different levels and numbers of positive axillary nodes.
  • The 5-year OS for patients with involved nodes confined to axillary level I was 74.4%, which was significantly better than that for involved nodes in level II or III or SLNM (49.2%, 52.8%, and 33.6%, respectively; P < .0001).
  • For one to three positive axillary nodes, the 5-year OS was 83.2%, which was significantly better than that for four to nine positive nodes, more than nine positive nodes, and SLNM (62.6%, 42.3%, and 33.6%, respectively).
  • There was no significant difference between SLNM and more than nine positive nodes.
  • Surgical removal of the supraclavicular nodes was a significantly better prognostic factor for OS after SLNM (P = .0327).
  • Good neck control either by surgery or chemotherapy achieved better survival.
  • [MeSH-major] Breast Neoplasms / mortality. Lymph Nodes / pathology. Lymphatic Metastasis
  • [MeSH-minor] Adult. Cohort Studies. Female. Humans. Medical Records. Middle Aged. Neoplasm Recurrence, Local. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16960682.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Morawietz L, Kuhnen C, Katenkamp D, Le Coutre P, Ladhoff A, Petersen I: Unusual sarcomatoid neoplasm of the lung suggesting a myofibrosarcoma. Virchows Arch; 2005 Dec;447(6):990-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual sarcomatoid neoplasm of the lung suggesting a myofibrosarcoma.
  • Myofibrosarcoma is a rare neoplasm that occurs mainly in the head and neck region and extremities of middle-aged patients.
  • Shortly after resection of the primary tumor, the patient showed multiple distant metastases in the contralateral lung, the mediastinal lymph nodes, the left adrenal gland, and the pectoral and deltoid muscle, which responded well to chemotherapy.
  • The case report will discuss the evidence for the final diagnosis of a primary pulmonary myofibrosarcoma and the differential diagnosis of sarcomatoid tumors of the lung.
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged. Nucleic Acid Hybridization. Pneumonectomy. Sarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1973 Jan;31(1):191-208 [4683037.001]
  • [Cites] Hum Pathol. 1996 Oct;27(10):1095-8 [8892598.001]
  • [Cites] Pathologe. 2003 Mar;24(2):128-35 [12673503.001]
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):219-28 [11176071.001]
  • [Cites] J Dermatol. 2001 Jul;28(7):383-7 [11510507.001]
  • [Cites] Am J Clin Pathol. 1994 Sep;102(3):331-40 [8085557.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12 ):1501-7 [11717539.001]
  • [Cites] Ultrastruct Pathol. 1993 Nov-Dec;17(6):611-22 [8122327.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Aug;137(1):33-42 [12377411.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):141-7 [9500214.001]
  • [Cites] Verh Dtsch Ges Pathol. 1998;82:75-82 [10095420.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):459-69 [11905413.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1228-38 [9777985.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):711-21 [15188137.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):393-4; author reply 394-6 [11981942.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Br J Cancer. 1997;75(1):79-86 [9000602.001]
  • [Cites] Cancer. 2004 Feb 25;102(1):41-54 [14968417.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):489-96 [9130998.001]
  • [Cites] Am J Surg Pathol. 1979 Dec;3(6):535-42 [534390.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):215-23 [15173943.001]
  • (PMID = 16158184.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


66. Oliapuram Jose B, Koerner P, Bertolone S, Patel CC, Spanos WJ Jr, Paris KJ, Silverman CL, Yashar CM: Pediatric Hodgkin's disease. J Ky Med Assoc; 2004 Mar;102(3):104-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common sites are: neck (84%), mediastinum (66%), and para-aortic lymph nodes (22%).
  • Twenty-five patients (78%) have nodular sclerosing type, 5 patients (16%) have mixed cellularity, and 2 patients (6%) have lymphocytic predominant type.
  • Eight patients (25%) were treated with radiation alone and 24 patients (75%) were treated with a combination of chemotherapy and radiation.
  • Of the radiation group, 5 patients were treated with mantle field; 2 patients with mantle, para-aortic node and splenic pedicles; and 1 patient with mini-mantle field.
  • The treatment was given with 4 or 6 mv photon, and the median dose was 36 Gray (range 32-40 Gy).
  • The median irradiation dose in the combination group was 25 Gy (range 21 Gy-36 Gy).
  • One patient with Stage III disease developed a second cancer (PNET: primitive neuroectodermal tumor) 111 months after combination treatment and has died.
  • One Stage IV patient has died with Hodgkin's disease 28 months after treatment with combination therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Mechlorethamine / therapeutic use. Prednisone / therapeutic use. Procarbazine / therapeutic use. Vinblastine / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Neoplasm Staging. Remission Induction. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15067795.001).
  • [ISSN] 0023-0294
  • [Journal-full-title] The Journal of the Kentucky Medical Association
  • [ISO-abbreviation] J Ky Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


67. Kutluhan A, Kiriş M, Kaya Z, Kisli E, Yurttaş V, Içli M, Kösem M: Squamous cell carcinoma of the lower lip and supra-omohyoid neck dissection. Acta Chir Belg; 2003 Jun;103(3):304-8
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the lower lip and supra-omohyoid neck dissection.
  • Primary treatment was applied to 28 patients of whom 23 were in stages I-II and five in stages III-IV.
  • Neck dissection was performed during primary lip resection in patients with palpable cervical lymph node involvement.
  • Patients with unpalpable cervical lymph nodes were divided into two subgroups: one was submitted to elective neck dissection (n = 11) and the other had isolated lip resection (n = 8).
  • Unilateral or bilateral selective supra-omohyoid neck dissection (SOHND) was performed according to the localisation of the disease.
  • Radical dissection was performed in a secondary intervention, when SOHND revealed lymph node metastases.
  • Radiotherapy and chemotherapy were applied for curative and/or adjuvant treatment in addition to surgery in patients with locoregional recurrence and metastatic lymph nodes or with perineural involvement.
  • RESULTS: Occult cervical metastasis within a single lymph node was found in one of the 11 No patients who underwent elective neck dissection.
  • Delayed neck metastasis developed in one of the eight patients in whom isolated lip resection (without neck exploration) was performed.
  • Neck metastasis was established histologically in four of five patients in stages III-IV.
  • One of the patients in this group died due to inoperable local recurrence in the neck, another died because of distant metastasis.
  • Our findings show the importance of elective neck dissection and intact surgical resection margins.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Lip Neoplasms / pathology. Lip Neoplasms / surgery. Lymph Node Excision
  • [MeSH-minor] Adult. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12914368.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


68. Nayak JV, Walvekar RR, Andrade RS, Daamen N, Lai SY, Argiris A, Smith RP, Heron DE, Ferris RL, Johnson JT, Branstetter BF 4th: Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT. Laryngoscope; 2007 Dec;117(12):2129-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT.
  • OBJECTIVE: To determine whether combined positron emission tomography and computed tomography (PET-CT) may be of value in deferring planned neck dissections for patients with advanced head and neck squamous cell carcinoma (HNSCC).
  • STUDY DESIGN: Observational study of patients with de novo cervical > or =N2 regional spread of HNSCC in a tertiary care academic medical center.
  • METHODS: Forty-three patients were identified who underwent post-treatment PET-CT within 6 months of completing neoadjuvant chemotherapy combined with radiation therapy (CRT).
  • The PET-CT was "positive" if the radiologist recommended tissue sampling or resection of cervical lymph nodes, or if there was progressive neck disease in the setting of distant metastatic disease.
  • RESULTS: Ten (22%) of the 43 post-treatment PET-CT studies were positive.
  • Seven of the 10 PET-CT scans (70% of positives) were true-positive given histologically-confirmed residual viable tumor or progressive disease including disease in the neck.
  • The 3 remaining studies (30% of positives) were false-positive PET-CT results, given resolution of fluorodeoxyglucose (FDG) avidity on subsequent imaging or tissue sampling demonstrating absence of viable tumor cells.
  • Of the 33 patients with negative PET-CTs in the neck, 1 patient had absence of FDG-avidity in the setting of malignant disease in the neck (3% false negatives); otherwise, patients with an initially negative PET-CT scan had no recurrences during the study (97% true negatives).
  • This corresponds to a sensitivity of 87.5% (7/8), a specificity of 91% (32/35), a positive predictive value of 70% (7/10), a negative predictive value of 97% (32/33), and accuracy of 91% (39/43) for PET-CT scans in the detection of cervical metastatic disease after CRT.
  • Overall, 37 (86%) of 43 patients were spared neck dissection using this technology without evidence of recurrent disease in the neck at extended follow-up.
  • CONCLUSIONS: Our results suggest that planned neck dissection after CRT for HNSCC may be deferred in favor of serial PET-CT imaging, and that sampling of areas of suspicious FDG-avid uptake can be rationally considered prior to therapeutic neck dissection.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy. Neck Dissection / methods. Positron-Emission Tomography / methods
  • [MeSH-minor] Combined Modality Therapy / methods. Follow-Up Studies. Humans. Lymphatic Metastasis. Neoplasm Staging / methods. Prognosis. Sensitivity and Specificity. Time Factors

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17921898.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Wenzel C, Fiebiger W, Dieckmann K, Formanek M, Chott A, Raderer M: Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the head and neck area: high rate of disease recurrence following local therapy. Cancer; 2003 May 1;97(9):2236-41
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the head and neck area: high rate of disease recurrence following local therapy.
  • BACKGROUND: Mucosa-associated lymphoid tissue (MALT) lymphoma is a distinct entity with specific clinical and pathologic features that may affect diverse organs.
  • MALT-lymphomas remain localized within their original environment for a long period of time.
  • As recent data have demonstrated a relatively high rate of multiorgan involvement at diagnosis, the authors have retrospectively evaluated 36 patients presenting with MALT-lymphoma in the head and neck area.
  • The authors focused on patients' disease localization, initial treatment, clinical course, and follow-up.
  • METHODS: Thirty-six patients with a histologically verified diagnosis of an extranodal marginal zone B-cell MALT-lymphoma arising in the head and neck area were included in this retrospective analysis.
  • RESULTS: Treatment consisted of surgical resection as the sole treatment in 4 patients (11%), surgical resection with consecutive radiotherapy in 13 patients (36%), radiotherapy alone in 11 patients (31%), chemotherapy in 2 patients (6%), surgical resection plus radiotherapy and chemotherapy in 4 patients (11%), and combined radiation and chemotherapy in 1 patient (3%).
  • Complete and partial disease remissions after initial treatment were achieved in 22 (61%) and 13 patients (36%), respectively, whereas one patient refused any therapy.
  • Four patients (11%) were lost to follow-up and 15 patients (43%) have had disease recurrence after a median time of 11 months (range, 3-80 months).
  • CONCLUSIONS: These data suggest that MALT-lymphomas of the head and neck area are preferentially treated using local modalities such as radiation and/or resection.
  • Clinical trials with application of systemic treatment are warranted for these patients.
  • [MeSH-major] Head and Neck Neoplasms / therapy. Lymphoma, B-Cell, Marginal Zone / therapy. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Radiotherapy Dosage. Remission Induction. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11317
  • (PMID = 12712477.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


70. Nguyen D, de la Rochefordière A, Chauveinc L, Cosset JM, Clough KB, Beuzeboc P, Mouret-Fourme E, Guyonnet M: [Chemoradiotherapy in locally advanced cancers of the uterine neck. Retrospective study of 92 patients treated at the Institute Curie between 1986 and 1998]]. Cancer Radiother; 2002 Jun;6(4):201-8
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemoradiotherapy in locally advanced cancers of the uterine neck. Retrospective study of 92 patients treated at the Institute Curie between 1986 and 1998]].
  • [Transliterated title] Chimioradiothérapie dans les cancers du col utérin localement évolués. Etude rétrospective de 92 patientes traitées à l'institut Curie de 1986 à 1998.
  • Recent publications reported that concurrent chemotherapy and pelvic radiation increased local control compared to radiotherapy alone.
  • Chemotherapy could also decrease metastatic recurrences.
  • Chemotherapy with 5FU-Cisplatin-Mitomycin C-Vindesin (protocol A) was performed for 43% of patients and 57% of them received 5FU-Cisplatin alone (protocol B).
  • Disease-free survival was correlated with therapeutic response.
  • In the surgery group, those patients with sterilized lymph nodes and tumours had also a higher DFS (76% vs 47%, p = 0.036).
  • 5FU-CDDP chemotherapy has a lower toxicity and is as effective as 5FU-CDDP-Mitomycin C-Vindesin protocol, in association with radiotherapy.
  • [MeSH-major] Radiotherapy, High-Energy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Gastrointestinal Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Paris / epidemiology. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome. Vindesine / administration & dosage

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12224486.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine; U3P01618RT / Fluorouracil
  •  go-up   go-down


71. Kung B, Aftab S, Wood M, Rosen D: Malignant melanoma metastatic to the thyroid gland: a case report and review of the literature. Ear Nose Throat J; 2009 Jan;88(1):E7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the case of a 68-year-old man who presented with a neck mass in the posterior triangle.
  • He underwent a left modified radical neck dissection, and the mass was discovered to be a positive lymph node.
  • Postoperatively, he declined to undergo radio- and chemotherapy.
  • He developed ventilator-dependent respiratory failure and required a subtotal thyroidectomy for the placement of a tracheostomy tube.
  • [MeSH-major] Melanoma / secondary. Neoplasm Invasiveness / pathology. Thyroid Neoplasms / secondary. Thyroid Nodule / pathology
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Follow-Up Studies. Humans. Immunohistochemistry. Lymph Nodes / pathology. Male. Neck Dissection. Neoplasm Staging. Risk Assessment. Thyroidectomy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19172560.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


72. Kawano T, Nakajima Y, Suzuki T, Haruki S, Ogiya K, Kawada K, Inokuchi M, Nishikage T, Yamada H, Kojima K, Nagai K: [Esophageal carcinoma - from the viewpoint of surgery]. Gan To Kagaku Ryoho; 2007 Jun;34(6):824-30
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therapeutic performance of the esophageal cancer has improved rapidly.
  • Now in the decision of therapeutic strategy not only life prognosis but also treatments-related morbidity and late term quality of life should be considered.
  • The most important factor of the improvement of esophageal cancer treatment is a progress in early detection of esophageal cancers and active use of treatment methods such as endoscopic mucosal resection.
  • In addition,the role of radiotherapy and chemotherapy has improved as an arm of multidisciplinary therapy,and the establishment of chemoradiotherapy as one of the standard therapy for esophageal cancer is also very important.
  • Surgical therapy is very effective in patients with localized esophageal tumor and the patient's satisfaction is high.
  • However, many problems are remained, and the improvement of diagnosis for metastasis and lessening surgical invasiveness and early/late complications are expected.
  • On the other hand, a new strategy such as chemoradiotherapy immediate after esophagectomy for the patients with possible residual tumor for improving therapeutic results may be considered under the status of reliable surgical procedures.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy / methods. Lymph Nodes / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Lymphatic Metastasis. Neck Dissection. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17565241.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


73. Erdağ TK, Karas C, Ikiz AO, Güneri EA, Ceryan K, Sarioğlu S: [The incidence of level I metastasis in laryngopharyngeal squamous cell carcinoma]. Kulak Burun Bogaz Ihtis Derg; 2003 Dec;11(6):166-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: The records of 126 patients who underwent primary tumor excision with radical neck dissection (RND) or its modifications for laryngeal or hypopharyngeal SCC were retrospectively reviewed.
  • Preoperative tumor and neck stages, the sites and the number of metastatic lymph nodes were recorded.
  • Patients treated with selective neck dissection (SND) or preoperative chemotherapy and/or radiation therapy were excluded.
  • RESULTS: Of 155 RND or modified RND performed for 113 laryngeal and 13 hypopharyngeal SCC, lymph node metastases were detected in 51 specimens, all of which spared level I.
  • CONCLUSION: Selective neck dissection sparing level I may be appropriate for clinically and radiologically N0 patients with laryngopharyngeal carcinoma.
  • [MeSH-minor] Female. Humans. Incidence. Lymph Node Excision. Male. Medical Records. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Turkey / epidemiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15567930.001).
  • [ISSN] 1300-7475
  • [Journal-full-title] Kulak burun boğaz ihtisas dergisi : KBB = Journal of ear, nose, and throat
  • [ISO-abbreviation] Kulak Burun Bogaz Ihtis Derg
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


74. Shibuya TY, Nugyen N, McLaren CE, Li KT, Wei WZ, Kim S, Yoo GH, Rogowski A, Ensley J, Sakr W: Clinical significance of poor CD3 response in head and neck cancer. Clin Cancer Res; 2002 Mar;8(3):745-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of poor CD3 response in head and neck cancer.
  • PURPOSE: The objective of our investigation was to prospectively study what the implications of an unresponsive CD3 receptor are on clinical outcome in advanced-stage head and neck cancer patients.
  • EXPERIMENTAL DESIGN: Lymph node mononuclear cells were purified from cancer patients and stimulated with immobilized anti-CD3 in vitro for 8 days.
  • Postoperative complications, length of hospitalization, toxicities associated with chemotherapy or radiation therapy, survival, and disease-free status were measured.
  • There were no phenotypic differences in lymph node T-cell subpopulations (CD3, CD4, CD8, CD28, CD45RO) between groups.
  • This is the first prospective study to confirm the importance of regional lymph node mononuclear cell CD3 receptor function in head and neck squamous cell carcinoma patients for tumor control.
  • [MeSH-major] Antigens, CD3 / immunology. Carcinoma, Squamous Cell / immunology. Head and Neck Neoplasms / immunology. Receptors, Cell Surface / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Immune Tolerance / immunology. In Vitro Techniques. Length of Stay. Lymph Nodes / immunology. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Phenotype. Postoperative Complications. Prognosis. Prospective Studies. Survival Rate. Thymidine / metabolism

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11895904.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / T32DC00026
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Receptors, Cell Surface; VC2W18DGKR / Thymidine
  •  go-up   go-down


75. Vargas H, Mouzakes J, Purdy SS, Cohn AS, Parnes SM: Follicular dendritic cell tumor: an aggressive head and neck tumor. Am J Otolaryngol; 2002 Mar-Apr;23(2):93-8
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular dendritic cell tumor: an aggressive head and neck tumor.
  • OBJECTIVE: To characterize the clinicopathologic features of head and neck follicular dendritic cell (FDC) tumor and report the experience of this entity at our institution.
  • STUDY DESIGN: Two case presentations are compared with a retrospective analysis of all published head and neck cases.
  • RESULTS: Thirty four cases of FDC tumor of the head and neck cases have been published.
  • Twenty five occurred in the cervical lymph nodes, 4 in the tonsils, 2 in the palate, 1 in the pharynx, 1 in the parapharyngeal region, and 1 in the thyroid gland.
  • Patients were treated with surgery (17), surgery and chemotherapy (8), and surgery and radiation (9).
  • After the primary treatment, 12 patients had no evidence of disease, whereas 5 were incurable.
  • Of these 13 patients who suffered recurrences, 4 had no evidence of disease after secondary treatment, 6 were alive with disease, and one was lost to follow up.
  • CONCLUSION: FDC tumor is a rare malignant neoplasm that can present in the head and neck region in both lymph nodes and extranodal sites.
  • Surgery has been the mainstay of treatment and should include diligent control of surgical margins.
  • The role of adjuvant therapy remains controversial.
  • We believe that FDC tumor should be viewed and treated as a moderately aggressive head and neck tumor.
  • [MeSH-major] Dendritic Cells, Follicular / pathology. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Middle Aged. Parotid Neoplasms / diagnosis. Parotid Neoplasms / pathology. Parotid Neoplasms / surgery. Severity of Illness Index. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Dendritic Cell Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.)
  • (PMID = 11893977.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


76. Courtois A, Foehrenbach H, Maszelin P, De Dreuille O, Garcia D, Kossowski M, Merlet P, Gaillard JF, Poncet JL: [Positron emission tomography in head and neck oncology: five cases]. Ann Otolaryngol Chir Cervicofac; 2001 Sep;118(4):254-60
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Positron emission tomography in head and neck oncology: five cases].
  • [Transliterated title] La tomographie à émission de positons en oncologie ORL. Une revue à propos de 5 cas.
  • FDG-PET (18-fluoro-desoxyglucose positron emission tomography) is a fonctionnal imaging method based on the high rate of glycolysis in different types of cancer-cells.
  • We report the first five cases where FDG-PET was used in France for head and neck cancers.
  • Although 18-FDG-PET cannot replace these techniques used to monitor size and structural changes in tumors and lymph nodes, it will be helpful in following their metabolic activity.
  • This diagnostic tool consequently is greatly helpful for detection and post-therapeutic evaluation of head and neck carcinomas and their recurrence.
  • 18-FDG-PET is currently under evaluation as a tool for detecting cervical lymph nodes and early assessment of response to chemotherapy.
  • [MeSH-major] Head and Neck Neoplasms / radionuclide imaging. Tomography, Emission-Computed
  • [MeSH-minor] Fluorodeoxyglucose F18. Humans. Laryngeal Neoplasms / radionuclide imaging. Lymphatic Metastasis / radionuclide imaging. Male. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasms, Unknown Primary / radionuclide imaging. Pharyngeal Neoplasms / radionuclide imaging. Prognosis. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11679846.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


77. Janinis J, Papadakou M, Panagos G, Panousaki A, Georgoulias V, Hatzidaki D, Lefantzis D, Dokianakis G: Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol; 2001 Jun;24(3):227-31
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer.
  • The purpose of this phase II trial was to evaluate the toxicity of a sequential chemoradiotherapy approach using docetaxel, cisplatin, and 5-fluorouracil (5-FU) (DCF) with granulocyte colony-stimulating factor support in previously untreated patients with locally advanced head and neck cancer (HNC).
  • Patients with locally advanced HNC, a World Health Organization performance status 0 to 2, and no prior history of chemotherapy or radiotherapy were included.
  • Treatment consisted of docetaxel 80 mg/m2 (1-hour infusion) on day 1, cisplatin 40 mg/m2 (1-hour infusion) on days 2 and 3, and 5-fluorouracil 1,000 mg/m2 (24-hour continuous infusion), on days 1 to 3, repeated every 28 days for a maximum of 4 cycles per patient.
  • Radiation therapy (RT) to the primary tumor site and neck lymph nodes was planned within 5 weeks of the last cycle of chemotherapy.
  • The primary tumor site received 60 to 70 Gy.
  • The most common acute nonhematologic toxicities from DCF induction chemotherapy included alopecia, mucositis, peripheral sensory neuropathy, onycholysis, and asthenia.
  • Febrile neutropenia developed in two patients and grade IV diarrhea in one patient.
  • There were no treatment-related deaths.
  • The overall response rate (RR) after DCF induction chemotherapy was 90% (95% confidence interval [CI]: 76.8-103.1%).
  • Sequential chemoradiotherapy with DCF and growth factor support is feasible and very active, with durable responses in patients with locally advanced head and neck cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Fluorouracil / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Paclitaxel / analogs & derivatives. Paclitaxel / therapeutic use. Taxoids
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11404490.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


78. Ferlito A, Silver CE, Rinaldo A, Smith RV: Surgical treatment of the neck in cancer of the larynx. ORL J Otorhinolaryngol Relat Spec; 2000 Jul-Aug;62(4):217-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of the neck in cancer of the larynx.
  • Current concepts in management of the clinically negative and clinically positive neck in laryngeal cancer are reviewed.
  • Occult disease in the neck not detected by physical and radiographic examination may also be difficult to identify on routine histologic examination.
  • The surgeon should be aware of the relatively high incidence of micrometastases in patients with laryngeal cancer to establish optimal treatment approaches.
  • Elective treatment of the neck is recommended for supraglottic tumors staged T2 or higher, and glottic or subglottic tumors staged T3 or higher.
  • The neck may be treated electively by either surgery or irradiation, but irradiation is best reserved for cases where that modality is employed for the primary tumor.
  • Elective neck dissection provides important information for prognostic purposes and therapeutic decisions, by establishing the presence, number, location and nature of occult lymph node metastases.
  • The selective lateral neck dissection (levels II, III and IV), unilateral or bilateral, is the procedure of choice for elective treatment.
  • Paratracheal nodes (level VI) should be dissected in cases of advanced glottic and subglottic cancer.
  • Complete radical or functional neck dissections are excessive in extent, as levels I and V are almost never involved.
  • Sentinel lymph node biopsy may fail to detect tumor on frozen section examination or may not reveal 'skip' metastases.
  • The clinically involved neck is usually treated by complete radical or functional neck dissection of levels I through V.
  • Selective neck dissection has been employed successfully in selected cases, particularly for N1 or occasionally N2 nodal involvement.
  • The selective neck dissection can be extended to include structures at risk.
  • More advanced disease has been treated in this manner often in association with adjuvant chemotherapy and/or irradiation.
  • While the benefit of adjuvant treatment is difficult to assess, it appears most useful in cases with extranodal spread of disease, a factor associated with the worst prognosis.
  • [MeSH-major] Laryngeal Neoplasms / surgery. Lymph Node Excision. Neck / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Immunohistochemistry. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10859523.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 114
  •  go-up   go-down


79. Bień S: [The history of radical dissection of cervical lymph nodes--in centenary of George Crile publication]. Otolaryngol Pol; 2006;60(1):5-8
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The history of radical dissection of cervical lymph nodes--in centenary of George Crile publication].
  • The history of surgical management of cervical lymph nodes metastases evolved from the XIX century period, when the lymph nodes metastases in head and neck cancer had been recognized as a stage of disease above the limits of rational surgical treatment.
  • Among the Pioneers of surgery of that time was Franciszek Jawdyński.
  • The second period dated from 1906 publication of George Crile, who postulated the necessity of surgical resection of primary tumor as well as regional head and neck lymph nodes and defined a procedure of radical block dissection of cervical lymph nodes ended, when Hughes Martin and his contemporaries established a comprehensive radical neck dissection as a universal standard procedure of head and neck surgery.
  • At present, not forgetting the value of radical neck dissection in treatment of cervical lymph nodes metastases, we return back to less mutilating surgical procedures, with preservation of non lymphatic structures and selective resections of regional group of nodes, due to the progress in non surgical treatment modalities (radiotherapy and chemotherapy) and new techniques of imaging and pathology.
  • [MeSH-major] Head and Neck Neoplasms / history. Neck Dissection / history. Neurosurgery / history
  • [MeSH-minor] History, 19th Century. History, 20th Century. Humans. Lymph Nodes / surgery. Neck. Neoplasm Staging / history. Poland. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16821533.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Biography; English Abstract; Historical Article; Journal Article
  • [Publication-country] Poland
  • [Personal-name-as-subject] Crile G; Jawdynski F; Hayes M
  •  go-up   go-down


80. Kurita H, Koike T, Narikawa JN, Sakai H, Nakatsuka A, Uehara S, Kobayashi H, Kurashina K: Clinical predictors for contralateral neck lymph node metastasis from unilateral squamous cell carcinoma in the oral cavity. Oral Oncol; 2004 Oct;40(9):898-903
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical predictors for contralateral neck lymph node metastasis from unilateral squamous cell carcinoma in the oral cavity.
  • The factors that predict contralateral (C-) lymph node metastasis (LNM) in patients with unilateral oral squamous cell carcinoma (SCC) were analyzed.
  • The impact of multiple clinicopathologic factors (sex, performance status, primary site, T-stage, number and level of ipsilateral LNM, growth type, histopathological grading, mode of invasion, extension across the midline, and systemic neoadjuvant/adjuvant chemotherapy) on time-to-C-LNM was assessed using the stepwise Cox proportional hazards model.
  • The results of this retrospective study suggested that patients with advanced tumors, multi-involvement of the ipsilateral neck nodes, or a higher degree of histopathological grading were at a higher risk for C-LNM.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies


81. Sugishita H, Ishida N, Yoshida M, Sato K, Doi T, Horiuchi A, Watanabe Y: [A case of cervical lymph node recurrence of advanced gastric cancer responding to combination therapy of S-1, CDDP and docetaxel]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1385-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of cervical lymph node recurrence of advanced gastric cancer responding to combination therapy of S-1, CDDP and docetaxel].
  • The post operative diagnosis was Stage IIIB (tubular adenocarcinoma, moderately-differentiated type, SE, N2, M0).
  • The patient's postoperative course was uneventful, and S-1 was administered as adjuvant chemotherapy.
  • However, about 14 months later, a gradual left cervical lymph node swelling became evident, with an increase in the level of the tumor marker CA19-9, suggesting recurrence of the gastric cancer.
  • After obtaining informed consent, S-1 (100 mg/body), cisplatin (60 mg/m2), and docetaxel (40 mg/m2) combination chemotherapy (DCS) was performed.
  • After 5 courses of DCS, the patient's swollen left cervical lymph nodes became non-palpable, and also undetectable by diagnostic imaging, together with normalization of the CA19-9 level.
  • At three months since the last chemotherapy, the patient showed no signs of recurrence.
  • DCS is a potentially effective treatment for recurrent gastric cancer with resistance to S-1.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Neck / pathology. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Taxoids / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Drug Combinations. Humans. Lymphatic Metastasis / radiography. Lymphatic Metastasis / radionuclide imaging. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Recurrence. Remission Induction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647733.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


82. Rusthoven KE, Raben D, Schneider C, Witt R, Sammons S, Raben A: Freedom from local and regional failure of contralateral neck with ipsilateral neck radiotherapy for node-positive tonsil cancer: results of a prospective management approach. Int J Radiat Oncol Biol Phys; 2009 Aug 1;74(5):1365-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Freedom from local and regional failure of contralateral neck with ipsilateral neck radiotherapy for node-positive tonsil cancer: results of a prospective management approach.
  • PURPOSE: To review the outcomes of a prospective management approach using ipsilateral neck radiotherapy in the treatment of node-positive squamous cell carcinoma of the tonsil with a well-lateralized primary lesion.
  • METHODS AND MATERIALS: Between August 2003 and June 2007, 20 patients who presented with squamous cell carcinoma of the tonsil, without involvement of the base of the tongue or midline soft palate, and with Stage N1-N2b disease were prospectively treated with radiotherapy to the primary site and ipsilateral neck.
  • In addition, 18 patients received concurrent chemotherapy.
  • Acute and late toxicity were prospectively evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3, and Radiation Therapy Oncology Group criteria.
  • Late Radiation Therapy Oncology Group grade 2 xerostomia occurred in 1 patient (5%).
  • CONCLUSION: In carefully selected patients with node-positive, lateralized tonsillar cancer, treatment of the ipsilateral neck and primary site does not appear to increase the risk of contralateral nodal failure and reduces late morbidity compared with historical controls.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / radiotherapy. Male. Middle Aged. Neck. Neoplasm Staging. Prospective Studies. Radiotherapy Dosage. Radiotherapy, Conformal / methods. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19168295.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Rengan R, Pfister DG, Lee NY, Kraus DH, Shah JP, Shaha AR, Ben-Porat LS, Zelefsky MJ: Long-term neck control rates after complete response to chemoradiation in patients with advanced head and neck cancer. Am J Clin Oncol; 2008 Oct;31(5):465-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term neck control rates after complete response to chemoradiation in patients with advanced head and neck cancer.
  • OBJECTIVES: To examine the long-term neck failure outcome in patients with advanced head and neck cancer treated on larynx/organ preservation protocols at Memorial Sloan-Kettering Cancer Center.
  • MATERIALS AND METHODS: Two hundred thirteen patients were enrolled from 1983 through 1995 on larynx/organ preservation protocols receiving induction chemotherapy followed by radiotherapy alone or with concomitant chemotherapy.
  • Eighty-six patients with node-positive disease received definitive chemoradiotherapy at Memorial Sloan-Kettering Cancer Center.
  • A median dose of 70 Gy was delivered.
  • RESULTS: Sixty-five patients with node-positive disease achieved a clinical complete response and were observed after chemoradiation without immediate neck dissection.
  • The crude rate of subsequent neck failure among those patients according to initial nodal classification was: N1 14% (3 of 21), N2: 15% (6 of 40), N3: 0% (0 of 4).
  • Patients who experienced a complete response to induction chemotherapy in the neck had improved overall survival (53% vs. 29%; P = 0.005) and a lower incidence of neck failure (10% vs. 24%; P = 0.14) when compared with those patients who had less than a complete response.
  • CONCLUSIONS: Our data suggests that in patients with advanced neck disease who have a clinical complete response in the neck to chemoradiation long-term neck control is 85% or greater without neck dissection.
  • Whether functional imaging or treatment response to induction chemotherapy would provide better discrimination of the 10% to 15% who may experience neck relapse is an important question for future research initiatives.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / therapy. Cisplatin / therapeutic use. Head and Neck Neoplasms / therapy. Lymph Nodes / pathology
  • [MeSH-minor] Combined Modality Therapy. Humans. Lymphatic Metastasis. Neoplasm Staging. Radiotherapy Dosage. Remission Induction. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838883.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


84. Kuehnemund M, Friedrichs N, Bootz F: [Synovial sarcoma of the head and neck]. Laryngorhinootologie; 2008 Jul;87(7):498-502
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synovial sarcoma of the head and neck].
  • Only 3 % of the SS show a primary manifestation in the head and neck region.
  • METHODS: A retrospective chart review (years 2002 - 2006) of our Department of Otorhinolaryngology, head and neck surgery, School of Medicine, Bonn, Germany, was performed searching for patients with primary head and neck manifestations of SS.
  • 3 patients underwent radical surgery followed by chemotherapy, 2 in combination with irradiation.
  • 1 patient underwent primary chemotherapy and irradiation.
  • The histological diagnosis was a biphasic SS as well as a monophasic SS in 2 patients respectively.
  • 2 patients were in complete remission at the recent follow-up, 1 patient died 14 months after diagnosis due to a lethal carotidal haemorrhage.
  • CONCLUSIONS: The aggressive character of the SS as well as its high recurrence rate afford a radical therapeutic scheme enclosing surgical, chemotherapeutical and radiological treatment as well as a thorough follow-up.
  • The genetic translocation t(X;18) leads the way to the right diagnosis.
  • The prognosis of head and neck SS must be considered as poor.
  • SS should be taken into consideration in head and neck tumors of unclear nature.
  • [MeSH-major] Otorhinolaryngologic Neoplasms / diagnosis. Sarcoma, Synovial / diagnosis
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Male. Mucin-1 / analysis. Neoplasm Staging. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231962.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Vimentin
  •  go-up   go-down


85. Malpica A, Deavers MT, Gershenson D, Tortolero-Luna G, Silva EG: Serous tumors involving extra-abdominal/extra-pelvic sites after the diagnosis of an ovarian serous neoplasm of low malignant potential. Am J Surg Pathol; 2001 Aug;25(8):988-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous tumors involving extra-abdominal/extra-pelvic sites after the diagnosis of an ovarian serous neoplasm of low malignant potential.
  • The involvement of extra-abdominal/extra-pelvic sites by serous tumors after the diagnosis of an ovarian serous neoplasm of low malignant potential is extremely rare.
  • Ten patients also received adjuvant therapy (radiotherapy, 2; chemotherapy and radiotherapy, 4; chemotherapy, 3; intraperitoneal 32P, 1).
  • The interval between the diagnosis of the ovarian neoplasm and the subsequent tumor involving an extra-abdominal/extra-pelvic site ranged from 4 to 240 months (mean 124 months).
  • Sites of extra-abdominal/extra-pelvic involvement and the number of cases were as follows: left neck lymph nodes (LNs), 4; left and right neck LNs, 1; pleura, 2; lung, 1; mediastinum, 1; chest wall, 1; axillary and chest LNs, 1; and vertebral body, 1.
  • Eight patients were treated with chemotherapy, 1 with radiotherapy, 2 with chemotherapy and radiotherapy, and 1 with surgery alone.
  • In this small series of cases, no definitive clinical or pathologic feature related to the occurrence of extra-abdominal/extra-pelvic serous tumors was found.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11474282.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Stiles BM, Mirza F, Port JL, Lee PC, Paul S, Christos P, Altorki NK: Predictors of cervical and recurrent laryngeal lymph node metastases from esophageal cancer. Ann Thorac Surg; 2010 Dec;90(6):1805-11; discussion 1811
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of cervical and recurrent laryngeal lymph node metastases from esophageal cancer.
  • BACKGROUND: Although patients with esophageal cancer (EC) often develop lymph node metastases in the cervical and recurrent laryngeal (CRL) distribution, lymphadenectomy in this field is rarely performed.
  • The purpose of this study was to determine factors associated with CRL node positivity and to determine the appropriate indications to perform a "three field" lymphadenectomy.
  • Predictors of positive CRL nodes were examined univariately, then selected for inclusion in a multivariate logistic regression model.
  • RESULTS: From 1994 to 2009, 185 patients had a three-field lymphadenectomy, of whom 46 patients (24.9%) had positive CRL nodes.
  • Eight patients had a major pathologic response after induction therapy.
  • On univariate analysis, variables significantly associated with positive CRL nodes included squamous cell histology, proximal location, advanced clinical presentation, the presence of clinical nodal disease, higher pT classification, and higher pN classification.
  • There was no reduction in the rate of positive CRL nodes after induction chemotherapy.
  • On multivariate analysis, higher pN classification (adjusted odds ratio 16.25, 95% confidence interval: 5.40 to 48.87; p < 0.0001) and squamous histology (adjusted odds ratio 6.04, 95% confidence interval: 2.21 to 16.56; p < 0.0001) predicted positive CRL nodes.
  • Low rates of positive CRL nodes are present with early clinical stage, with pT0-2 tumors, and with pN0 classification, particularly in patients with adenocarcinoma and gastroesophageal junction tumors.
  • [MeSH-major] Esophageal Neoplasms / secondary. Lymph Node Excision / methods. Lymph Nodes / pathology. Lymphatic Metastasis / diagnosis. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Combined Modality Therapy. Female. Follow-Up Studies. Humans. Incidence. Larynx. Male. Neck. Neoplasm Staging. New York / epidemiology. Odds Ratio. Prognosis. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Laryngeal cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 21095315.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / UL1-RR024996
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  •  go-up   go-down


87. Xie FY, Peng M, Hu WH, Han F, Wang X, Xu HM: [Prophylactic irradiation of cervical lymph nodes for Stage-N0 nasopharyngeal carcinoma]. Chin J Cancer; 2010 Jan;29(1):106-10
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prophylactic irradiation of cervical lymph nodes for Stage-N0 nasopharyngeal carcinoma].
  • BACKGROUND AND OBJECTIVE: It is controversial for the irradiation level and dose of the regional prevention for naspharyngeal cancer (NPC) with one or both cervical lymph node-negative neck.
  • The study was to analyze the proophylactic irradiation of cervical lymph nodes for Stage -N0 NPC patients.
  • Before treatment, each patient underwent CT or MRI.
  • Doses applied were 60-80 Gy to the nasopharynx and 46-64 Gy to the neck without lymphadenopathy.
  • Consecutive radiotherapy was performed employing conventional fractionation of 2 Gy/fraction, once a day, for a total of five fractions per week.
  • Chemotherapy was administered to 60 patients.
  • A total of 205 patients with stage-N0 NPC were divided into an upper-neck irradiation group and an entire-neck group.
  • A total of 88 patients received irradiation to the upper neck and 117 to the entire neck.
  • The rate of regional failure for the upper-neck group and the entire-neck group were 2.27% and 0%, respectively (P>0.05).
  • The 1-and 3-year OS for the upper-neck group were 97.7% and 94.2%, and the 1- and 3-year OS for the entire-neck group were 97.4% and 91.9% (P=0.950).
  • The 1- and 3-year DFS for the upper-neck group were 96.6% and 92.9%, and the 1- and 3-year DFS for the entire-neck group were 95.6% and 90.9% (P= 0.730).
  • CONCLUSIONS: Prophylactic irradiation to the upper neck does not influence regional failure or long-term survival in the patients with stage-N0 NPC.
  • Radiotherapy to the upper neck (levels II, III, VA) is recommended for the patients with stage-N0 NPC.
  • [MeSH-major] Lymph Nodes / pathology. Lymphatic Irradiation. Lymphatic Metastasis / prevention & control. Nasopharyngeal Neoplasms / radiotherapy. Radiotherapy, High-Energy / methods
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Nasopharynx / radiation effects. Neck / radiation effects. Neoplasm Recurrence, Local. Neoplasm Staging. Particle Accelerators. Proportional Hazards Models. Radiotherapy Dosage. Retrospective Studies. Sex Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038321.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


88. Llorente JL, Pérez-Escuredo J, Alvarez-Marcos C, Suárez C, Hermsen M: Genetic and clinical aspects of wood dust related intestinal-type sinonasal adenocarcinoma: a review. Eur Arch Otorhinolaryngol; 2009 Jan;266(1):1-7
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and clinical aspects of wood dust related intestinal-type sinonasal adenocarcinoma: a review.
  • Intestinal-type sinonasal adenocarcinoma (ITAC) is a rare epithelial cancer of the nasal cavities and paranasal sinuses.
  • Metastasis to regional lymph nodes and distant metastasis are less frequent (10%).
  • Standard therapeutic modalities include surgery followed by radiotherapy in advanced stages, sometimes with chemotherapy treatment.
  • This review aims to describe the clinico-pathological characteristics of this relatively unknown tumor and to summarize the knowledge on genetic and chromosomal analyses up to the present time.
  • [MeSH-major] Adenocarcinoma / etiology. Neoplasm Recurrence, Local / pathology. Occupational Exposure / adverse effects. Paranasal Sinus Neoplasms / etiology. Wood / adverse effects
  • [MeSH-minor] Dust. Female. Genetic Predisposition to Disease / epidemiology. Humans. Immunohistochemistry. Male. Molecular Biology. Neoplasm Staging. Prognosis. Survival Analysis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Apoptosis. 2004 Mar;9(2):123-30 [15004509.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):335-41 [14716769.001]
  • [Cites] Surg Neurol. 1994 Aug;42(2):98-104 [8091301.001]
  • [Cites] Arch Otorhinolaryngol. 1988;245(1):1-15 [2839136.001]
  • [Cites] J Otolaryngol. 1993 Apr;22(2):86-90 [8515523.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1345-57 [15001537.001]
  • [Cites] Head Neck. 1998 May;20(3):224-31 [9570628.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4901-6 [15611505.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10 ):1080-3 [15452164.001]
  • [Cites] Mod Pathol. 2005 Mar;18(3):315-9 [15492756.001]
  • [Cites] Int J Cancer. 2000 Mar 1;85(5):740-2 [10699958.001]
  • [Cites] Acta Otolaryngol Suppl. 1998;535:1-16 [9725790.001]
  • [Cites] Mod Pathol. 1995 May;8(4):421-6 [7567943.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1109-19 [12360473.001]
  • [Cites] Br Med J. 1968 Jun 8;2(5605):587-96 [5654629.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Feb;127(2):141-6 [11177030.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Jul;135(1):135-9 [16815198.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):99-106 [15068833.001]
  • [Cites] Head Neck. 2004 Feb;26(2):136-44 [14762882.001]
  • [Cites] Acta Otolaryngol. 2002 Mar;122(2):197-201 [11936913.001]
  • [Cites] Acta Otorhinolaryngol Belg. 1996;50(1):19-24 [8669267.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Jul;122(7):765-8 [8663951.001]
  • [Cites] Cell. 2004 Sep 17;118(6):671-4 [15369667.001]
  • [Cites] Am J Surg Pathol. 1986 Mar;10 (3):192-202 [3953940.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4817-25 [15256451.001]
  • [Cites] Carcinogenesis. 2005 Sep;26(9):1513-9 [15860506.001]
  • [Cites] Acta Otolaryngol. 1986 May-Jun;101(5-6):501-8 [3727983.001]
  • [Cites] Acta Otorrinolaringol Esp. 2008 May;59(5):235-8 [18501159.001]
  • [Cites] Acta Otorrinolaringol Esp. 2004 Jan;55(1):27-33 [15108619.001]
  • [Cites] Laryngoscope. 2008 Mar;118(3):437-43 [18176354.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2154-9 [18186150.001]
  • [Cites] Am J Surg Pathol. 1982 Dec;6(8):803-9 [7168462.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):255-64 [10421261.001]
  • [Cites] Head Neck. 2006 Oct;28(10 ):909-15 [16906516.001]
  • [Cites] Am J Otolaryngol. 1995 Mar-Apr;16(2):109-14 [7793504.001]
  • [Cites] J Pathol. 2005 Oct;207(2):207-15 [16041693.001]
  • [Cites] Mod Pathol. 1996 Mar;9(3):199-204 [8685214.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):196-203 [12673679.001]
  • [Cites] Am J Epidemiol. 1994 Aug 15;140(4):340-9 [8059769.001]
  • [Cites] Acta Otolaryngol. 1984 Sep-Oct;98(3-4):321-34 [6496064.001]
  • [Cites] Cancer Lett. 1998 Apr 10;126(1):59-65 [9563649.001]
  • [Cites] Cancer. 1984 Aug 1;54(3):482-8 [6733678.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1988 Sep;114(9):996-9 [3408582.001]
  • (PMID = 18560862.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dust
  • [Number-of-references] 47
  •  go-up   go-down


89. Chopra S, Gupta T, Agarwal JP, Budrukkar A, Ghosh-Laskar S, Dinshaw K: Re-irradiation in the management of isolated neck recurrences: current status and recommendations. Radiother Oncol; 2006 Oct;81(1):1-8
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re-irradiation in the management of isolated neck recurrences: current status and recommendations.
  • Recent times have witnessed significant improvements in outcome for head and neck squamous cell carcinomas.
  • Isolated neck recurrence, although uncommon, occurs in 5-7% of patients after radical treatment.
  • This review attempts to systematically analyze the therapeutic options for patients with isolated neck recurrence following radical treatment for the primary and draining cervical lymph nodes, with a special emphasis on re-irradiation.
  • Salvage neck dissection offers the best chance of cure to patients with resectable neck recurrences.
  • Re-irradiation with or without chemotherapy may be considered for unresectable neck recurrences.
  • The role of chemotherapy continues to evolve and is presently not optimally defined.
  • There is lack of high-quality evidence pertinent to salvage therapy leading to vast variations in practice.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Practice Guidelines as Topic. Salvage Therapy / methods
  • [MeSH-minor] Humans. Neck Dissection / mortality. Radiotherapy Dosage. Retreatment / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16971009.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 44
  •  go-up   go-down


90. Laskar SG, Agarwal JP, Srinivas C, Dinshaw KA: Radiotherapeutic management of locally advanced head and neck cancer. Expert Rev Anticancer Ther; 2006 Mar;6(3):405-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapeutic management of locally advanced head and neck cancer.
  • Head and neck cancer management has undergone several paradigm shifts for several relevant reasons.
  • From the dismal experience with the use of radiotherapy as the sole modality in the treatment of this group of patients with advanced disease, radiotherapy has been evaluated as an adjuvant for the same group of patients who had undergone successful surgery.
  • Predictors of recurrence after surgical resection are: positive margins of resection; extranodal spread in involved nodes; perineural invasion; and presence of two or more involved regional lymph nodes.
  • Realization of the advantages of a combination of chemotherapy with radiotherapy has had a major impact on the management of these cancers.
  • Multiple organ conservation strategies in the management of locally advanced head and neck cancers have evolved over the years.
  • However, the meta-analyses of impact of chemotherapy in various settings reveal that concomitant chemoradiotherapy is superior to any of the other regimens.
  • Increasing use of computed tomography, magnetic resonance imaging and positron emission tomography scan images has resulted in better visualization of target volumes and critical structures.
  • Delineation of these structures is of paramount importance and has resulted in a profound change in conformal treatment planning.
  • Better understanding of the physical aspects of delivery of radiotherapy and the advent of modern treatment planning systems have led to the development of conformal techniques.
  • Although the benefit of these techniques on survival have yet to be demonstrated, there is evidence to suggest that they reduce treatment-related toxicities significantly and facilitate dose escalation.
  • Increased knowledge of radiobiology has led to the development of various altered fractionation regimens in the management of locally advanced head and neck cancers.
  • Discovery of cell-cycle kinetics and signal transduction pathways has led to the unearthing of several potential targets for targeted therapy.
  • All of these approaches to improve the therapeutic gain would be incomplete without evaluating their effect on the quality of life of these patients.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Cycle. Combined Modality Therapy. Humans. Kinetics. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Risk Factors. Signal Transduction. Survival

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16503857.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 63
  •  go-up   go-down


91. Jia SS, Wang YY, Pei R, Sun J: [Pathological feature and management of occult lymphatic metastasis in supraglottic carcinoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2005 Feb;40(2):103-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (3) no preoperative radiotherapy and (or) chemotherapy.
  • Ipsilateral supraomohyoid neck dissections were performed in all cases.
  • Lymph nodes were studied histologically according to the levels of dissection.
  • RESULTS: Six of 30 cases were positive nodes histologically in first operation, 3 were occurrence neck metastasis in opposite side during follow ups.
  • 527 lymph nodes were collected in all of 30 patients, average 17.6 nodes in every side neck.
  • Ten positive lymph nodes histologically were harvested.
  • The distribution of metastatic lymph nodes was 9 in level II, 1 in level III, no in level I.
  • N0 recurrence in larynx and (or) at the neck after dissection.
  • The selective lateral neck dissection of level II, III and occasionally, level IV was recommended.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Laryngeal Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16429726.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


92. Yao M, Smith RB, Graham MM, Hoffman HT, Tan H, Funk GF, Graham SM, Chang K, Dornfeld KJ, Menda Y, Buatti JM: The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys; 2005 Nov 15;63(4):991-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment.
  • PURPOSE: The role of neck dissection after definitive radiation for head-and-neck cancer is controversial.
  • We select patients for neck dissection based on postradiation therapy (post-RT), computed tomography (CT), and [18F] fluorodeoxyglucose positron emission tomography (FDG PET).
  • We summarize the clinical outcomes of patients treated with this policy to further elucidate the role of FDG PET in decision making for neck dissection after primary radiotherapy.
  • These patients had stage N2A or higher head-and-neck squamous cell carcinoma and had complete response of the primary tumor after definitive radiation with or without chemotherapy.
  • PET or computed tomography (CT) scans were performed within 6 months after treatment.
  • Neck dissection was performed in patients with residual lymphadenopathy (identified by clinical examination or CT) and a positive PET scan.
  • Those without residual lymph nodes and a negative PET were observed without neck dissection.
  • For patients with residual lymphadenopathy, but a negative PET scan, neck dissection was performed at the discretion of the attending surgeon and decision of the patient.
  • There was a total of 70 heminecks available for analysis (17 patients had bilateral neck disease).
  • Of these, 4 had neck dissection and were pathologically negative.
  • The remaining 17 were observed without neck dissection.
  • There was a total of 42 heminecks without residual lymph nodes on post-RT CT imaging or clinical examination with a negative PET.
  • They were also observed without neck dissection.
  • Six of them had neck dissection and 1 had fine-needle aspiration of a residual node; 3 contained residual viable cancer and 4 were pathologically negative.
  • CONCLUSION: For patients who have no evidence of residual lymphadenopathy and a negative FDG PET scan 12 weeks after definitive radiation, neck dissection can be safely withheld.
  • Even in cases in which small residual lymphadenopathy was observed, regional recurrences have not occurred when the post-RT PET scan was negative and neck dissection was withheld.
  • For patients with large residual lymphadenopathy (greater than 2.0-3.0 cm in size) but a negative post-RT FDG PET, further studies with longer follow-up are necessary to determine the appropriateness of withholding neck dissection.
  • [MeSH-major] Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Head and Neck Neoplasms / radionuclide imaging. Neck Dissection. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm, Residual. Retrospective Studies. Tomography, Emission-Computed. Tongue Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):633; author reply 633-4 [16690448.001]
  • (PMID = 16099601.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


93. Doki Y, Ishikawa O, Takachi K, Miyashiro I, Sasaki Y, Ohigashi H, Murata K, Yamada T, Noura S, Eguchi H, Kabuto T, Imaoka S: Association of the primary tumor location with the site of tumor recurrence after curative resection of thoracic esophageal carcinoma. World J Surg; 2005 Jun;29(6):700-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The site of surgical failure in cases of thoracic esophageal cancer (TEC) may be affected by the vertical location of the cancer in this longitudinal organ, suggesting the need to select the mode of adjuvant therapy based on location.
  • We classified 501 TECs (92% squamous cell carcinomas) that underwent curative surgery without preoperative treatment as 13% upper thoracic (Ut), 51% middle thoracic (Mt), and 36% lower thoracic (Lt) lesions.
  • Recurrent disease was discovered in 180 (36%) of the patients during a postoperative survey, most frequently in the cervical nodes (19%), liver (18%), abdominal paraaortic nodes (17%), and upper mediastinal nodes (17%).
  • Although postoperative survival rates were similar (5-year survival: Ut 51%, Mt 55%, Lt 54%), the tumor recurrence site was significantly affected by the TEC vertical location, with recurrence in the cervical and upper mediastinal nodes being most frequent for Ut and Mt cases and in the liver and abdominal paraaortic nodes for Lt cases.
  • Insufficient surgical lymph node clearance could be assessed by the recurrence index (RI), defined as the frequency of metastasis at recurrence divided by that at surgery.
  • The RI was significantly lower for the upper abdominal nodes (4%, 8/184) than the lower mediastinal nodes (15%, 19/123) or the upper mediastinal nodes (19%, 30/154).
  • Regional radiotherapy might be expected to have an adjuvant effect on Ut/Mt tumors and systemic chemotherapy on Lt tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Abdomen. Esophagectomy. Humans. Lymph Node Excision. Mediastinum. Neck. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 11):11-8 [14506599.001]
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):340-6 [8605557.001]
  • [Cites] Dis Esophagus. 2001;14(2):98-103 [11553217.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1315-8 [11100340.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 1989 Mar;90(3):364-76 [2770680.001]
  • [Cites] Hepatogastroenterology. 2003 Jan-Feb;50(49):115-20 [12630005.001]
  • [Cites] Recent Results Cancer Res. 2000;155:123-33 [10693246.001]
  • [Cites] Dis Esophagus. 2001;14(3-4):191-6 [11869318.001]
  • [Cites] Surgery. 2001 Nov;130(5):792-7 [11685188.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):364-72; discussion 372-3 [8092902.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 9):46-55 [12908136.001]
  • [Cites] World J Surg. 1997 Mar-Apr;21(3):275-81 [9015170.001]
  • [Cites] Oncol Rep. 2003 Jan-Feb;10(1):81-7 [12469149.001]
  • [Cites] World J Surg. 1994 Mar-Apr;18(2):266-72 [8042333.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2003 May;15(3):98-108 [12801045.001]
  • [Cites] Surgery. 2002 Jul;132(1):93-9 [12110801.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):581-7 [11685019.001]
  • [Cites] J Am Coll Surg. 2000 Sep;191(3):232-7 [10989896.001]
  • [Cites] Gan To Kagaku Ryoho. 1995 Sep;22(11):1538-41 [7574753.001]
  • [Cites] Surgery. 2003 Apr;133(4):368-74 [12717353.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Jan;11(1):89-109, viii [11928803.001]
  • [Cites] Am J Surg. 1999 Jun;177(6):503-6; discussion 507 [10414703.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1616-23 [12655517.001]
  • [Cites] Surgery. 2003 May;133(5):479-85 [12773975.001]
  • (PMID = 16078126.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Dieckmann KP, Albers P, Classen J, De Wit M, Pichlmeier U, Rick O, Müllerleile U, Kuczyk M: Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol; 2005 Mar;173(3):824-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Late relapse was defined as recurrence of disease more than 2 years after completion of primary treatment.
  • Several parameters were analyzed including age, clinical stage, treatment at primary presentation, occurrence of prior early relapse, interval to L/R, tumor markers, site of relapse, and mode and outcome of L/R treatment.
  • Possible effects of various clinical parameters on treatment results were studied by multivariate statistical analysis.
  • A total of 75% of nonseminomas but only 20% of seminomas had disseminated disease at first presentation, while 51 patients with nonseminoma had initially received chemotherapy. alpha-Fetoprotein was increased in 45 patients (of 59 eligible) with nonseminoma at L/R, human chorionic gonadotropin in 12 cases. alpha-Fetoprotein levels greater than 100 U/l indicated poor prognosis.
  • Topographically relapses were mainly confined to lymph nodes of the abdomen, chest and neck.
  • Anatomically L/R presents as lymphadenopathy of abdomen, chest or neck.
  • Treatment should include surgery in nonseminoma.
  • Seminomas and otherwise chemotherapy naive cases might respond to chemotherapy only.
  • Particular risk groups for late relapse are nonseminoma with prior early relapse, patients receiving chemotherapy for disseminated disease at first presentation and those with pure teratoma.
  • [MeSH-major] Germinoma / epidemiology. Neoplasm Recurrence, Local / epidemiology. Testicular Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Humans. Male. Middle Aged. Retrospective Studies. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711278.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Wu Z, Ma JY, Yang JJ, Zhao YF, Zhang SF: Primary small cell carcinoma of esophagus: report of 9 cases and review of literature. World J Gastroenterol; 2004 Dec 15;10(24):3680-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To analyze the clinical manifestations, pathological features and treatment of primary small cell carcinoma (SCC) of the esophagus and to review the literature on this entity.
  • METHODS: The records of 9 patients with primary esophageal small cell carcinoma were examined and the demographic data, presenting symptoms, methods of tumor diagnosis, and types of treatment given, response to treatment, pathologic findings, and clinical outcome were reviewed.
  • Features of mixed patterns of histological differentiation and lymph node metastases were specifically sought.
  • They underwent radical resection, regional lymph node clearance and esophageal-stomach anastomosis in thorax or at neck.
  • Metastasis was present in 7 of 9 adjacent lymph nodes.
  • They received adjuvant systemic chemotherapy and local radiation therapy after discharge.
  • During follow-up, three patients developed multiple liver, brain, lung and bone metastases and died between 5 and 18 mo after the diagnosis.
  • Three patients developed widespread metastasis disease and died between 18 and 37 mo after the diagnosis.
  • Radical resection combined with chemotherapy and radiotherapy is helpful in limited stage cases.
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15534932.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC4612018
  •  go-up   go-down


96. Suárez C, Rodrigo JP, Ferlito A, Devaney KO, Rinaldo A: Merkel cell carcinoma of the head and neck. Oral Oncol; 2004 Sep;40(8):773-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma of the head and neck.
  • Merkel cell carcinoma (MCC) is a rare neuroendocrine neoplasm of the skin.
  • The tumor most frequently affects elderly patients, with a preference for the head and neck.
  • MCC has a propensity for spreading to regional lymph nodes, either at presentation or as a first site of relapse.
  • Sentinel lymph node positivity is helpful in predicting the risk of recurrence or metastasis in patients with MCC.
  • Complete surgical resection is the mainstay of treatment of the primary tumor.
  • Tumor resections are recommended to include a 2-3-cm tumor-free margin around the primary lesion when possible, but this is often difficult to achieve in the head and neck, where Mohs micrographic surgery has proved to be effective.
  • The role of adjuvant radiation therapy is controversial.
  • The role of adjuvant chemotherapy in diminishing the risk of subsequent systemic recurrence in patients with positive nodes remains undefined.
  • Overall response rates to combination chemotherapy for surgically unresectable distant metastatic disease are generally high, although responses are transient.
  • Overall survival of head and neck MCC at 5 years postoperatively ranks between 40% and 68%.
  • [MeSH-major] Carcinoma, Merkel Cell. Head and Neck Neoplasms. Skin Neoplasms
  • [MeSH-minor] Chromosome Aberrations. Female. Humans. Immune Tolerance. Male. Prognosis. Sentinel Lymph Node Biopsy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15288830.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 61
  •  go-up   go-down


97. Dulguerov P, Allal AS, Calcaterra TC: Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol; 2001 Nov;2(11):683-90
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our objective was to review recent developments in diagnosis, staging, and treatment of esthesioneuroblastoma (ENB).
  • A meta-analysis of publications between 1990 and 2000 was carried out, and studies were classified according to their main subject: origin/aetiology of ENB, histopathological diagnosis, and treatment.
  • Histopathological diagnosis remains difficult and is based on results of antigen expression detected through a panel of antibodies by immunohistochemistry.
  • In patients with metastases in cervical lymph nodes (on average 5% of the total) survival was 29%, compared with 64% for patients with N0 disease (odds ratio 5.1).
  • Survival according to treatment modalities was 65% for surgery plus radiotherapy, 51% for radiotherapy and chemotherapy, 48% for surgery, 47% for surgery plus radiotherapy and chemotherapy, and 37% for radiotherapy alone.
  • The histopathological grading according to Hyams and the presence of cervical lymph-node metastases emerged as prognostic factors.
  • A combination of surgery and radiotherapy seems to be the optimum approach to treatment.
  • The exact role of chemotherapy in treatment protocols is still unclear.
  • The role of elective neck dissection is unclear.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / pathology. Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity / pathology. Nose Neoplasms / pathology. Nose Neoplasms / therapy
  • [MeSH-minor] Humans. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11902539.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Number-of-references] 92
  •  go-up   go-down


98. Hocwald E, Korkmaz H, Yoo GH, Adsay V, Shibuya TY, Abrams J, Jacobs JR: Prognostic factors in major salivary gland cancer. Laryngoscope; 2001 Aug;111(8):1434-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: A retrospective study of 78 patients with major salivary gland cancer (64 parotid and 14 submandibular gland) who underwent surgery for definitive treatment from 1976 to 1996.
  • A select group of patients also received adjuvant radiation (56%) and/or chemotherapy (13%).
  • Age, gender, tumor site, T-stage, facial paralysis, histologic neck involvement, perineural invasion, and cancer grade were analyzed with respect to disease-free survival.
  • The role of adjuvant treatment in terms of clinical outcome was also investigated.
  • Examining clinical and histologic features one at a time, we found poorer prognosis was associated with submandibular tumors compared with parotid (P =.02), higher T-stage (P =.001), positive cervical nodes (P <.001), perineural invasion (P =.002), and high-grade or adenoid cystic tumors (P =.002).
  • A multivariable analysis indicated that positive lymph nodes (P =.07) and perineural invasion (P =.03) were important histologic predictors of shorter disease-free survival.
  • Receipt of both adjuvant radiation and cisplatin-based chemotherapy (P =.05) was an independent predictor of longer disease-free survival.
  • CONCLUSION: Our study indicated that the presence of positive lymph nodes and perineural invasion is important independent predictors of disease-free survival.
  • Our limited data also suggest that adjuvant chemotherapy and radiation therapy may improve disease-free survival.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11568581.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Uehara M, Shiraishi T, Tobita T, Nonaka M, Asahina I: Antitumor effects on primary tumor and metastatic lymph nodes by superselective intra-arterial concurrent chemoradiotherapy for oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Aug;110(2):172-7
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor effects on primary tumor and metastatic lymph nodes by superselective intra-arterial concurrent chemoradiotherapy for oral cancer.
  • The total radiation doses to the primary tumor and neck were 60.0 Gy and 40.0 Gy, respectively.
  • RESULTS: Complete response of the primary tumor was achieved in all 13 patients; complete response of neck node metastasis was achieved in 5 out of 6 patients.
  • CONCLUSION: This strategy is quite effective for oral cancer at both the primary site and metastatic lymph nodes, and it has the potential to be curative in advanced cases that are inoperable.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Lymph Nodes. Mouth Neoplasms / drug therapy. Mouth Neoplasms / radiotherapy. Neck
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Catheterization / methods. Combined Modality Therapy. Humans. Infusions, Intra-Arterial / methods. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Remission Induction. Temporal Arteries. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20382050.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Langerman A, Plein C, Vokes EE, Salama JK, Haraf DJ, Blair EA, Stenson KM: Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg; 2009 Nov;135(11):1133-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer.
  • OBJECTIVE: The role of neck dissection following chemoradiotherapy (CRT) for locoregionally advanced head and neck cancer is an area of active debate.
  • Patients who have a complete radiographic response may not need dissection, and the extent of neck dissection necessary for those patients with residual disease is unclear.
  • DESIGN: Retrospective review of data from a prospectively collected database of patients with locoregionally advanced head and neck cancer treated as part of a phase 2 study of induction chemotherapy followed by concurrent CRT.
  • The results of post-CRT neck computed tomography (CT) imaging and pathologic analysis of the neck dissection specimens were compared to evaluate correlation between radiographic and pathologic response.
  • Overall, 209 neck levels were dissected.
  • Radiologic complete response in the neck was achieved in 39 patients, all of whom had pathologic specimens negative for tumor cells.
  • Ten patients (20%) had a total of 14 neck levels with residual disease on CT imaging.
  • CONCLUSIONS: Neck levels with residual disease on post-CRT CT imaging warrant removal.
  • However, neck levels without evidence of disease on post-CRT CT imaging are unlikely to harbor cancer, which lends further support to the concept of basing neck dissection on post-CRT staging and performance of limited neck dissections for patients with limited residual disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Head and Neck Neoplasms / radiotherapy. Lymph Nodes / pathology. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Biopsy. Follow-Up Studies. Humans. Lymphatic Metastasis. Neck Dissection / methods. Neoplasm Staging / methods. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917927.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement